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ABSTRACT
According to current models, matrix proteins are synthesized in cytosolic
ribosomes and bound by the shuttling receptor PEX5. The vast majority of those
proteins possess a peroxisomal targeting signal type 1 (PTS1), a tripeptide sequence
at their C termini, usually with the sequence S-K-L. A minor part of the peroxisomal
matrix proteins contains instead a PTS2 signal, an N-terminal degenerated
nonapeptide with the consensus sequence R-(L/V/I/Q)-X2-(L/V/I/H)-(L/S/G/A)-X-
(H/Q)-(L/A). The interaction between PEX5 and matrix proteins containing a PTS1 is
direct, while the PEX5-PTS2 interaction requires an adaptor protein, PEX7. The
cytosolic PEX5-cargo protein complex then interacts with the peroxisomal
docking/translocation module (DTM), which ultimately results in PEX5 insertion into
this protein machinery. PEX5 is then monoubiquitinated at a conserved cysteine
residue, a mandatory modification for its ATP-dependent dislocation back into the
cytosol by the Receptor Export Module (REM). Finally, monoubiquitinated PEX5 is
deubiquitinated by a conjugation of enzymatic and non-enzymatic mechanisms.
Although our knowledge on the general properties of the PEX5-mediated
import pathway is considerable, the exact step of this pathway where cargo proteins
are translocated across the organelle membrane is still ill-defined. In an attempt to fill
in this gap, the import mechanism of pre-thiolase, a PTS2 protein, has been recently
characterized. The data suggest that translocation of pre-thiolase across the
peroxisomal membrane occurs before ubiquitination of the DTM-embedded PEX5,
presumably during insertion of the receptor into the DTM. However, whether this is a
unique feature of PTS2 proteins emerging from the participation of PEX7 in this
process, or a general property of the peroxisomal protein import machinery, remained
unknown.
The aim of this work was to characterize the translocation mechanism of the
major class of matrix proteins, the PTS1 proteins. For this purpose, it was necessary
to develop a PTS1-centered in vitro import system. A major limitation of such system
is the low import yields obtained when using these matrix proteins as reporters. We
found that such limitation could be overcome by pre-incubating the reporter protein
with recombinant PEX5, prior to the in vitro import reaction. Indeed, this resulted in a
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remarkable improvement of the import yields of several PTS1 proteins. One of these
proteins was Sterol Carrier Protein x (SCPx), a protein involved in the last step of the
peroxisomal β-oxidation of fatty acids. Using this strategy, we have characterized the
import mechanism of SCPx. Our results show that the in vitro import efficiencies of
SCPx were not affected by the use of AMP-PNP or by apyrase treatment, although
PEX5 export and PEX5 monoubiquitination, respectively, are blocked under these
conditions. Moreover, a PEX5 mutated version which is not a substrate for
monoubiquitination, and consequently is not a substrate for the REM, was as efficient
as the normal PEX5 in transporting SCPx to the peroxisome. Altogether, these data
demonstrate that neither PEX5 monoubiquitination nor its export are required for
SCPx import. Similar results were obtained for 2,4-dienoyl-CoA reductase (DECR2),
another PTS1 protein, thus suggesting that this is a general property of the
mechanism of PTS1 protein translocation. Peroxisome fractionation analyses
indicated that at least a fraction of the imported SCPx was completely translocated to
the peroxisomal matrix, in a process, again, requiring neither cytosolic ATP hydrolysis
nor ubiquitination of PEX5. The PTS1-centered in vitro import system developed in
this work also allowed us to observe for the first time a mechanistically distinct
docking step of the PEX5-cargo complex at the DTM. These results support a model
in which translocation of proteins across the peroxisomal membrane occurs before
the first cytosolic ATP-dependent step (i.e., before PEX5 ubiquitination),
concomitantly with the insertion of the receptor into the docking/translocation
machinery.
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RESUMO
Segundo os modelos actuais, as proteínas da matriz peroxissomal são
sintetizadas em ribossomas citosólicos e endereçadas para o organelo pelo receptor
peroxisomal PEX5. A maioria das proteínas matriciais contêm um sinal de
endereçamento peroxisomal do tipo 1 (PTS1), um tripéptido presente no C-terminal,
normalmente com a sequência S-K-L. Uma minoria possui um sinal PTS2, um
nonapéptido degenerado presente no N-terminal destas proteínas, cuja sequência
consenso é R-(L/V/I/Q)-X2-(L/V/I/H)-(L/S/G/A)-X-(H/Q)-(L/A). A PEX5 interage
directamente com proteínas matriciais que contenham um PTS1, enquanto a
interacção com proteínas PTS2 requer uma proteína adaptadora, a PEX7. Na
membrana peroxissomal, o complexo PEX5-proteína matricial interage com o módulo
peroxissomal de docking e translocação de proteínas (DTM), conduzindo à inserção
da PEX5 nesta maquinaria proteica. A PEX5 é posteriormente monoubiquitinada
numa cisteína conservada, uma modificação obrigatória para a sua remoção do DTM
para o citosol pelo Módulo de Exportação do Receptor (REM), num processo
dependente de ATP. Finalmente, a PEX5 monoubiquitinada, é desubiquitinada no
citosol por uma combinação de mecanismos enzimáticos e não enzimáticos.
Apesar do nosso conhecimento sobre a via de importação mediada pela
PEX5 ser já bastante detalhado, a informação relativa ao passo exacto desta via
onde as proteínas da matriz peroxisomal são translocadas através da membrana do
organelo ainda é escassa. Recentemente, numa tentativa de esclarecer este ponto,
foi caracterizado o mecanismo de importação da pré-tiolase, uma proteína com um
sinal PTS2. Os dados obtidos sugerem que a translocação da pré-tiolase através da
membrana peroxisomal ocorre antes do passo de ubiquitinação da PEX5,
presumivelmente durante a sua inserção no DTM. No entanto, se isto é uma
característica única da via de importação de proteínas com um sinal PTS2 que
emerge do envolvimento da PEX7 ou uma propriedade geral do sistema de
importação peroxissomal, permanecia por descobrir.
O objectivo deste trabalho foi caracterizar o mecanismo de translocação da
classe principal de proteínas matriciais, as proteínas que contêm um PTS1. Para o
efeito, foi necessário desenvolver um sistema de importação in vitro centrado numa
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proteína PTS1. A grande limitação deste sistema é o baixo rendimentos de
importação quando se usam proteínas matriciais PTS1 como proteínas repórter.
Descobrimos que essa limitação poderia ser ultrapassada pré-incubando a proteína
repórter com PEX5 recombinante antes da reacção de importação in vitro. De facto,
isto resultou num aumento significativo dos rendimentos de importação de várias
proteínas PTS1. Uma destas proteínas é a Sterol Carrier Protein x (SCPx), uma
proteína envolvida no último passo da via de β-oxidação de ácidos gordos. Usando
esta estratégia, caracterizámos o mecanismo de importação da SCPx. Os resultados
obtidos demonstram que as eficiências da sua importação não foram afectadas pelo
uso de AMP-PNP, nem pelo tratamento com apirase, apesar da exportação e
monoubiquitinação da PEX5, respectivamente, estarem bloqueadas nestas
condições. Adicionalmente, uma versão mutada da PEX5 incapaz de ser
monoubiquitinada e que, consequentemente, não é exportada pelo REM, foi tão
eficiente como a PEX5 normal no transporte da SCPx para o peroxissoma. Em
conjunto, os dados obtidos demonstram que nem a monoubiquitinação da PEX5,
nem a sua exportação são necessárias para a importação da SCPx. Resultados
semelhantes foram obtidos para a 2,4-dienoil-CoA redutase (DECR2), outra proteína
PTS1, sugerindo que esta é uma propriedade geral do processo de translocação de
proteínas PTS1. Análises de fraccionamento peroxissomal demonstraram que pelo
menos uma fracção da SCPx importada já tinha sido completamente translocada
para a matriz peroxissomal, num processo, novamente, independente da hidrólise de
ATP citosólico e da monoubiquitinação da PEX5. O sistema de importação in vitro
centrado numa proteína PTS1 desenvolvido neste trabalho, permitiu ainda, pela
primeira vez, a observação de um passo mecanisticamente distinto de docking do
complexo PEX5-proteína matricial no DTM. Estes resultados suportam um modelo no
qual a translocação de proteínas através da membrana peroxissomal ocorre antes do
primeiro passo dependente de ATP citosólico (i.e., antes da ubiquitinação da PEX5),
concomitantemente com a inserção do receptor na maquinaria peroxisomal de
docking e translocação.
ABBREVIATIONS
x
ABBREVIATIONS
AAA ATPases associated with diverse cellular activities
ABC ATP-Binding Cassette
ACOX1 Acyl-CoA oxidase 1
ADHAPS Alkyl-DHAP synthase
AGT Alanine glyoxylate aminotransferase
ALDP Adrenoleukodystrophy protein
AMACR 2-methylacyl-CoA racemase
BSA Bovine serum albumin
C. elegans Caenorhabditis elegans
CHO Chinese hamster ovary
DBP D-bifunctional protein
DECR2 2,4-dienoyl-CoA reductase
DHAP Dihydroxyacetone phosphate
DHAPAT DHAP acyltransferase
DTM Docking/translocation module
DTT Dithiothreitol
DUB Deubiquitinating enzyme
E1 Ubiquitin-activating enzyme
E2 Ubiquitin-conjugating enzyme
E3 Ubiquitin ligase
E-64 N-(trans-epoxysuccinyl)-L-leucine 4-guanidinobutylamide
EDTA Ethylenediamine tetraacetic acid
ER Endoplasmic reticulum
FIS1 Fission 1
GSH Glutathione
GST Gluthathione-S-transferase
H. polymorpha Hansenula polymorpha
IAA Iodoacetamide
IgG Immunoglobulin G
MFF Mitochondrial fission factor
ABBREVIATIONS
xi
MOPS 4-morpholinepropanesulfonic acid
mPTS Membrane peroxisomal targeting signal
NALD Neonatal Adrenoleukodystrophy
NTP Nucleoside triphosphate
PAGE Polyacrylamide gel electrophoresis
PBDs Peroxisome biogenesis disorders
PEX Peroxin
PH1 Primary Hyperoxaluria type 1
PHYH Phytanoyl-CoA hydroxylase
PIM Peroxisomal import machinery
PK Proteinase K
PMP Peroxisome membrane protein
PMSF Phenylmethylsulfonyl fluoride
PNS Postnuclear supernatant
PTS1 Peroxisomal targeting signal 1
PTS2 Peroxisomal targeting signal 2
REM Receptor export module
RING Really interesting new gene
S. cerevisiae Saccharomyces cerevisiae
SCP2 Sterol carrier protein 2
SCPx Sterol carrier protein x
SDS Sodium dodecylsulfate
SEM Buffer containing sucrose, EDTA and MOPS
SH3 Src homology 3 domain
TCA Trichloroacetic acid
TPR Tetratricopeptide repeats
Tris Tris(hydroxymethyl)aminomethane
Ub Ubiquitin
Ubal Ubiquitin aldehyde
Ub-PEX5 Monoubiquitinated PEX5
VLCFA Very long chain fatty acid
X-ALD X-linked Adrenoleukodystrophy
ABBREVIATIONS
xii
WD Tryptophan-aspartate repeat
Y. lipolytica Yarrowia lipolytica
ZS Zellweger syndrome
ZSDs Zellweger spectrum disorders
1. INTRODUCTION
1.   INTRODUCTION
2
1.1.Peroxisome structure and function
Peroxisomes are unique organelles present in almost all eukaryotic cells.
They were first described in 1954, by Rhodin, as microbodies (Rhodin, 1954).
Peroxisomes owe their current name to De Duve and Baudhuin who, in 1966, defined
them as a cellular compartment harboring at least one oxidase, forming hydrogen
peroxide, and catalase, the enzyme that decomposes it (De Duve & Baudhuin, 1966).
Peroxisomes can display a very heterogeneous morphology that varies among
different species, tissues and prevailing environmental or development conditions
(reviewed in (Lazarow & Fujiki, 1985; Purdue & Lazarow, 2001; Schrader & Fahimi,
2006; Fransen, 2012)). Typically, they are spherical or ovoid, exhibiting a size range
between 0.1-1 μm in diameter. However, they may also appear as elongated, tubular,
or reticular structures (Schrader et al, 1996). These single-membrane organelles lack
DNA or an independent protein synthesis machinery (Kamiryo et al, 1982; Douglass
et al, 1973; Leighton et al, 1968). In electron microscopy, they are structurally
characterized by a very electron-dense protein-rich granular matrix. In liver and renal
cells from several organisms they may contain crystalline inclusions comprising urate
oxidase or other enzymes (Figure 1) (Leighton et al, 1968; Tsukada et al, 1966; Zaar
& Fahimi, 1991).
Figure 1. Rat liver peroxisomes.
Electron micrograph of peroxisomes (P) from a rat liver postnuclear supernatant where crystalline
cores of urate oxidase () can be observed. Scale bar, 0.2 μm (micrograph kindly taken by Prof. Dr.
Manuel Teixeira da Silva, IBMC, Porto, Portugal).
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Peroxisomes are very often referred to as “multipurpose organelles” due to
their involvement in several metabolic and non-metabolic pathways (see Table 1).
They are highly versatile and dynamic, and although often specialized according to
the organism and cell type, all peroxisomes share two common conserved features:
the metabolism of hydrogen peroxide and β-oxidation of fatty acids (Cooper &
Beevers, 1969; Lazarow & De Duve, 1976; Breidenbach et al, 1968; Kawamoto et al,
1978). In mammalian cells, β-oxidation is distributed between peroxisomes and
mitochondria. Short, medium and some long chain fatty acids are exclusively oxidized
in mitochondria, whereas very long chain fatty acids (VLCFA) can only be processed
in peroxisomes (Wanders & Waterham, 2006a; Poirier et al, 2006). In fungi and
plants, β-oxidation is instead a strictly peroxisomal process (Poirier et al, 2006). Fatty
acid α-oxidation is another peroxisomal process in mammals which is required for the
degradation of branched-chain fatty acids, like phytanic acid (Wanders et al, 2011;
Croes et al, 1996; Jansen et al, 1996; Mihalik et al, 1995). In agreement with their
diverse metabolic function, peroxisomes display a striking heterogeneity regarding
their enzyme content (Islinger et al, 2010; Hu et al, 2012; Gabaldón, 2010). Actually,
some highly specialized peroxisomes have even different designations. For instance,
peroxisomes of germinating seeds are often designated glyoxysomes due to their
enrichment in enzymes of the glyoxylate cycle (Olsen, 1998). Similarly, peroxisomes
of trypanosomes are known as glycosomes, as they contain several enzymes
involved in glycolysis (Michels et al, 2006). Another example is provided by the
Woronin bodies which are very specialized peroxisomes, whose function is to seal
septal pores, preventing cytoplasmic bleeding when hyphae of filamentous fungi are
damaged (Pieuchot & Jedd, 2012). Among other peroxisomal functions are some
species/tissue-specific tasks (see also Table 1). In plants, for instance, peroxisomes
also participate in the synthesis of jasmonic acid, auxin and biotin, and are involved
both in photorespiration in leaves and nitrogen transport in roots (Olsen, 1998; Hu et
al, 2012; Islinger et al, 2012; Tanabe et al, 2011). In mammals, peroxisomes are also
involved in the synthesis of bile acids and plasmalogens (Wanders, 2013; Fidaleo,
2010; Fransen, 2012; Terlecky et al, 2012; Islinger et al, 2012). In some fungi,
peroxisomes also participate in the synthesis of β-lactam antibiotics (Penicillium
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chrysogenum) and biotin (Aspergillus oryzae) (Tanabe et al, 2011; Islinger et al,
2012). Finally, in methylotrophic yeasts, peroxisomes are crucial for the growth in
methanol as a sole source of carbon and energy (Yurimoto et al, 2011; Islinger et al,
2012). In many of the biochemical pathways peroxisomes do not work alone. Rather
they act as members of a coordinated cellular machinery, physically and functionally
interacting with other subcellular compartments, namely mitochondria and the
endoplasmic reticulum (ER) (Bonekamp & Schrader, 2012; Braverman & Moser,
2012; Camões et al, 2009; Van Veldhoven, 2010; Kohlwein et al, 2013; Wanders,
2013).
Recently, a non-metabolic biological task has been added to the list of
mammalian peroxisomes functions. Specifically, it was suggested that peroxisomes
can act as signaling platforms, involved not only in transient and complex regulatory
interactions of cellular processes but also in antiviral signaling, providing a rapid and
short-term protection during viral infection (Dixit et al, 2010; Ribeiro et al, 2012; Zhang
et al, 2013).
Table 1. Diversity of peroxisomal functions
Peroxisomal Functions
Fatty acid β-oxidation
Degradation of polyamines
Detoxification of Reactive Oxygen Species (ROS)
Glyoxylate cycle
Biosynthesis of etherphospholipids
Fatty acid α-oxidation
Synthesis of bile acids
Synthesis of pheromones
Viral innate immune defense
Glycolysis
Degradation of icosanoids
Degradation of xenobiotics
Photorespiration
Nitrogen transport
Synthesis of jasmonic acid and auxin
Synthesis of toxins
Synthesis of β-lactam antibiotics
Methanol and methylamines metabolism
Synthesis of docosahexaenoic acids
Synthesis of biotin
Adapted from (Fransen, 2012; Hu et al, 2012; Terlecky et al, 2012; Fidaleo, 2010; Islinger et al, 2012;
Olsen, 1998; Bartoszewska et al, 2011; Kunze & Hartig, 2013; Kunze et al, 2006; Wanders, 2013).
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1.2.Peroxisomes and disease
Although peroxisomes were discovered more than fifty years ago, they
became a pivotal subject in the scientific community only after the identification of the
so-called, peroxisomal disorders (see Table 2). The first link between peroxisomes
and an inherited lethal disorder was established in 1973, with the discovery that
patients affected with the Zellweger cerebro-hepato-renal syndrome lack peroxisomes
in hepatocytes and renal tubule cells (Goldfischer et al, 1973). Many other genetic
disorders ethiologically related to peroxisome function were discovered in the 1980s
and 1990s, thus establishing the real importance of peroxisomes in human health and
disease (Goldfischer et al, 1973; Wanders et al, 1988; Zellweger et al, 1988; Heikoop
et al, 1990; Biardi et al, 1994; Fujiki, 2000; Wanders, 2004b; Delille et al, 2006;
Waterham & Ebberink, 2012).
Table 2. Peroxisomal disorders and metabolic pathways affected
Peroxisomal Disorders Metabolic PathwayAffected
Peroxisomal single Enzyme Deficiencies (PEDs)
2-Methylacyl-CoA racemase (AMACR) deficiency (AMACR deficiency)
β-oxidation of fatty acids
Acyl-CoA oxidase (ACOX1) deficiency (ACOX1 deficiency)
D-Bifunctional protein (DBP) deficiency (DBP deficiency)
Sterol Carrier Protein x (SCPx) deficiency (SCPx deficiency)
X-linked Adrenoleukodystrophy (ALDP deficiency)
Refsum disease (PHYH deficiency) α-oxidation of fatty acids
Rhizomelic chondrodysplasia punctata Type 2 (DHAPAT deficiency) Ether phospholipid
synthesisRhizomelic chondrodysplasia punctata Type 3 (ADHAPS deficiency)
Acatalasaemia (catalase deficiency) H2O2 metabolism
Primary Hyperoxaluria Type 1 (AGT deficiency) Glyoxylate detoxification
Bile acid-CoA:amino acid N-acyltransferase deficiency (BAAT deficiency) Bile acid synthesis
Peroxisome Biogenesis Disorders (PBDs)
Zellweger Spectrum Disorders (ZSDs)
Several pathways affected
Zellweger Syndrome (ZS)
Neonatal Adrenoleukodystrophy (NALD)
Infantile Refsum Disease (IRD)
PEX11β deficiency
Rhizomelic chondrodysplasia punctata (RCDP) Type 1
Adapted from (Delille et al, 2006; Fidaleo, 2010; Wanders, 2013; Thoms & Gärtner, 2012).
Abbreviations: ALDP, adrenoleukodystrophy protein; PHYH, phytanoyl-CoA hydroxylase; DHAPAT,
dihydroxyacetone phosphate (DHAP) acyltransferase; ADHAPS, alkyl- DHAP synthase; AGT, Alanine
glyoxylate aminotransferase.
1.   INTRODUCTION
6
Peroxisomal disorders represent a spectrum of genetically inherited metabolic
diseases that are characterized by the lack of peroxisomes or an impairment of one
or more peroxisomal functions (Wanders, 2004b). They are rare multisystemic
disorders frequently affecting the nervous system (Barry & O’Keeffe, 2013; Poll-The &
Gartner, 2012). The severity of these diseases varies according to the extent of the
impairment of peroxisome functions.
Peroxisomal disorders can be classified into two major groups: 1) the
peroxisomal single enzyme deficiencies, and 2) the peroxisome biogenesis disorders
(reviewed in (Delille et al, 2006; Gould & Valle, 2000; Sacksteder & Gould, 2000;
Steinberg et al, 2006; Wanders, 2004a; Fidaleo, 2010)).
1.2.1. Peroxisomal single enzyme deficiencies
Peroxisomal single enzyme deficiencies (see Table 2) result from mutation in a
gene encoding a peroxisomal enzyme or transporter thus affecting one specific
peroxisomal function, such as α- or β-oxidation of fatty acids, ether phospholipid
synthesis, glyoxylate detoxification or H2O2 metabolism (Wanders & Waterham,
2006b). In these disorders, the peroxisomes are intact and functional, except for the
single metabolic pathway affected by the mutation.
X-linked Adrenoleukodystrophy (X-ALD) is the most common peroxisomal
single enzyme deficiency, with an estimated birth incidence of 1 in 17,000 newborns
(Engelen et al, 2012). X-ALD is a neurodegenerative and progressive disorder
caused by mutations in the ABCD1 gene (reviewed in (Wang et al, 2011) and (Kemp
& Wanders, 2010)). The ABCD1 gene encodes a peroxisomal ATP-Binding Cassette
(ABC) transporter protein, the Adrenoleukodystrophy protein (ALDP), whose function
is to transport CoA thioesters of VLCFA from the cytosol to the peroxisomal matrix
(Mosser et al, 1993; Wiesinger et al, 2013). ALDP deficiency thus impairs VLCFA β-
oxidation and leads to an accumulation of VLCFA in cells and tissues (Moser et al,
1999). By largely undefined mechanisms, this accumulation results in neurological
degeneration by nerve demyelination (Asheuer et al, 2005). The nervous system
loses the ability to fully coordinate nerve impulses and, consequently, X-ALD patients
can experience motor skill loss, sensory deficit, seizures, dementia and blindness
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(Kemp et al, 2012). X-ALD treatments are very limited and essentially symptomatic.
Some dietary treatments, such as Lorenzo’s oil combined with a VLCFA-poor diet,
reduce VLCFA levels but do not stop the disease’s progression (Ferrer et al, 2010;
Aubourg et al, 1993). Presently, hematopoietic stem cell transplantation is the only
curative approach, but it is only effective in patients with early stages of cerebral
symptoms (Peters et al, 2004; Ferrer et al, 2010).
Another example of a peroxisomal single enzyme deficiency is provided by
Primary Hyperoxaluria type 1 (PH1), a disease caused by a deficiency in peroxisomal
alanine glyoxylate aminotransferase (AGT), an enzyme that catalyzes the conversion
of glyoxylate into glycine (Danpure & Jennings, 1986). In the absence of AGT,
peroxisomal glyoxylate accumulates and is reduced to glycolate or oxidized to
oxalate. Unlike glycolate, which is soluble and therefore can be excreted in urine,
oxalate precipitates as calcium oxalate and accumulates in liver and other organs,
especially in the kidney (Wanders & Waterham, 2006b; Danpure, 2006). In some
cases, PH1 is not caused by AGT loss of catalytic activity but instead by its
mislocalization to mitochondria (Danpure et al, 2003). PH1 is characterized by
hyperoxaluria associated or not with hyperglycolic aciduria, calcium oxalate
urolithiasis or nephrocalcinosis and, as mentioned above, progressive loss of renal
function over time. In contrast to other peroxisomal disorders, there are some
therapeutic options for the treatment of PH1 which target the reduction of oxalate
synthesis and the increase of calcium oxalate solubility (reviewed in (Salido et al,
2012)).
1.2.2. Peroxisome biogenesis disorders (PBDs)
The second group of peroxisomal disorders are the PBDs (Table 2). These
diseases occur in approximately 1:50,000 live births in the United States (Steinberg et
al, 2006; Barry & O’Keeffe, 2013) and represent a spectrum of autosomal recessive
metabolic disorders that are caused by mutations in genes encoding peroxins (PEX),
i.e., peroxisomal proteins required for peroxisome biogenesis and maintenance (see
Table 3) (Fujiki et al, 2012b; Waterham & Ebberink, 2012). Therefore, when a PEX
gene is affected, several or all peroxisomal functions are impaired and peroxisomes
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may be completely absent. In many cases, it is still possible to observe peroxisomal
remnants in patient cells. These structures are known as peroxisomal ghosts (Brown
& Baker, 2003; Purdue & Lazarow, 2001; Santos et al, 1988b). Peroxisomal ghosts
are empty organelles that lack all, or almost all, their matrix content due to a defect in
peroxisome matrix protein import (even though they possess the normal repertoire of
membrane proteins). The effects of the loss of functional peroxisomes include an
accumulation of toxic peroxisomal substrates, such as VLCFA or phytanic acid, and a
depletion of essential metabolites normally produced in peroxisomes (Lee &
Raymond, 2013; Sacksteder & Gould, 2000; Steinberg et al, 2006). One example of
the latter are the plasmalogens whose complete or major depletion is at the basis of
both bone and brain deficiencies observed in PBDs patients (Braverman & Moser,
2012).
PBDs can be caused by defects in any of, at least, fourteen different PEX
genes (see Table 3) (Fidaleo, 2010; Fujiki et al, 2012b; Gould & Valle, 2000;
Steinberg et al, 2006). Thirteen of these genes have been implicated in the so-called
Zellweger Syndrome Spectrum disorders (ZSDs), while mutations in the remaining
one (the PEX7 gene) are the cause of the disorder Rhizomelic Chondrodysplasia
Punctata (RCDP) type 1 (Waterham & Ebberink, 2012). The ZSDs include three
overlapping clinical entities that share liver disease, neurodevelopmental delay,
retinopathy and perceptive deafness but differ in the severity of symptoms (Brosius &
Gartner, 2002; Wanders & Waterham, 2005; Waterham & Ebberink, 2012). The
Zellweger Syndrome (ZS), or cerebro-hepato-renal syndrome, is the most severe
form of the spectrum. It is characterized by the absence of functional peroxisomes in
all cells. ZS patients present hypotonia, craniofacial dysmorphism, weakness, severe
brain dysfunction associated with neuronal migration defects at birth and usually die
within the first year of age (Braverman et al, 2013; Brosius & Gartner, 2002).
Neonatal adrenoleukodystrophy (NALD) is an intermediate form of ZSDs, with
patients presenting clinical symptoms similar, yet less severe, to those of ZS patients.
The life expectancy is also longer in NALD than in ZS (Waterham & Ebberink, 2012;
Wanders & Waterham, 2005; Braverman et al, 2013). The mildest form of the ZSDs is
the Infantile Refsum disease (IRD). Patients with IRD do not show neuronal migration
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disorder or progressive white matter disease (Braverman et al, 2013; Waterham &
Ebberink, 2012; Poll-The & Gartner, 2012). Clinical presentations of IRD include
hypotonia, hearing loss, vision impairment, and developmental delay (Braverman et
al, 2013; Wanders & Waterham, 2005; Waterham & Ebberink, 2012; Poll-The &
Gartner, 2012). IRD is a slow progression disorder, with patients frequently surviving
until 30 years of age. Similarly to NALD, IRD patients may present some level of
mosaicism with some cells presenting residual peroxisomes (Matsui et al, 2012;
Steinberg et al, 2006; Matsumoto et al, 2001).
Recently, a new mild ZSD was identified in a Dutch patient presenting atypical
biochemical features for a PBD. Specifically, this patient had normal biochemical
peroxisome parameters, including plasma concentrations of VLCFA, phytanic and
pristanic acid (Ebberink et al, 2012). However, analyses of peroxisome morphology in
skin fibroblasts of this patient revealed elongated and enlarged organelles. After
analysis of several candidate genes, a homozygous point mutation in the PEX11β
gene was found (Ebberink et al, 2012), in agreement with the known function of
PEX11β in peroxisome proliferation and division (Ebberink et al, 2012; Koch et al,
2010; Huber et al, 2012).
The last of PBDs, RCDP type 1, is caused by mutations in the PEX7 gene
(Braverman et al, 1997; Purdue et al, 1997). These mutations result in the
mistargeting of only a subset of peroxisomal proteins, producing a biochemical,
cellular, and clinical phenotype distinct from the ZSDs (Braverman et al, 1997; Purdue
et al, 1997; Mohamadynejad et al, 2013). Although peroxisomes present a normal
morphology, several functions are compromised, namely plasmalogen synthesis and
α-oxidation of fatty acids. RCDP type 1 is characterized by bone abnormalities
(shortening of the upper extremities – rhizomelia; stippled epiphyses –
chondrodysplasia punctate; low stature; facial dysmorphism), cataracts, microcephaly
and psychomotor retardation (Braverman et al, 2013; Jansen et al, 2004).
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Table 3. Genes affected in Peroxisome Biogenesis Disorders (PBDs)
Gene Phenotype PeroxisomeGhosts Pathway affected
PEX1 ZS, NALD, IRD + Matrix protein import (Receptor recycling)
PEX2 ZS, IRD + Matrix protein import (Receptor recycling)
PEX3 ZS - Membrane protein import
PEX5 ZS, NALD + Matrix protein import
PEX6 ZS, NALD + Matrix protein import (Receptor recycling)
PEX7 RCDP type1 + Matrix protein import
PEX10 ZS, NALD + Matrix protein import (Receptor recycling)
PEX11β mild ZSS + Peroxisome proliferation/division
PEX12 ZS, NALD, IRD + Matrix protein import (Receptor recycling)
PEX13 ZS, NALD + Matrix protein import (Docking/Translocation)
PEX14 ZS + Matrix protein import (Docking/Translocation)
PEX16 ZS - Membrane protein import
PEX19 ZS - Membrane protein import
PEX26 ZS, NALD, IRD + Matrix protein import (Receptor recycling)
Adapted from: (Fujiki et al, 2012b; Nagotu et al, 2012; Waterham & Ebberink, 2012; Thoms & Gärtner,
2012).
1.3.Peroxisome biogenesis
It is generally accepted that peroxisome biogenesis involves, at least
conceptually, three steps: 1) biogenesis/assembly of the peroxisomal membrane; 2)
import of all of the matrix content; and 3) peroxisome proliferation.
The identification of the proteins (and corresponding genes) involved in these
three aspects of peroxisome biogenesis was essentially performed using two main
strategies. The vast majority of the PEX genes were identified by genetic
complementation studies in yeast and Chinese Hamster Ovary (CHO) cell mutants
(Tsukamoto et al, 1990; Fujiki et al, 2000; Erdmann et al, 1989; Liu et al, 1992; Gould
et al, 1992). Homology searches by screening the human expressed sequence tag
database using yeast PEX genes further contributed for the isolation of human
ortholog genes (Weller et al, 2003; Fujiki et al, 2006). More recently, another strategy
has been used to identify other components involved in peroxisome biogenesis: the
biochemical isolation of enzyme activities using standard protein purification
procedures. This strategy allowed the identification of components of the machinery
that also participate in other cellular pathways, namely the mammalian E2s E2D1/2/3,
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the mammalian deubiquitinase USP9X, the yeast deubiquitinase UBP15 and
mammalian AWP1 ((Grou et al, 2008, 2012; Debelyy et al, 2011; Miyata et al, 2012;
Bozza & Zhuang, 2011); see also below).
Presently, more than thirty peroxins are known in different organisms (see
Table 4). Strikingly, however, only sixteen of them are present in mammals (Kiel et al,
2006; Schlüter et al, 2006; Zolman et al, 2005; Goto et al, 2011). Apparently,
evolution led to a simpler architecture of the peroxisomal biogenesis machinery (see
Figure 1 in (Grou et al, 2009a)). This simplification was probably achieved by the
acquisition of extra functions by the corresponding mammalian/plant proteins.
PEX18/21 (Saccharomyces cerevisae) and PEX20 (other yeasts and fungi) (see also
section 1.3.3.), for example, are species-specific peroxins absent in mammals and
plants, whose role in the targeting of a subset of matrix proteins has been embraced
by the receptor PEX5 of these organisms (Lazarow, 2006; Schliebs & Kunau, 2006).
Similarly, yeasts and plants possess a peroxisomal dedicated E2, PEX4 and its
membrane anchor PEX22, while in mammals, the E2 peroxisomal function has been
embraced by the multipurpose cytosolic E2s, E2D1/2/3 (UbcH5a/b/c in mammals)
(Grou et al, 2008; Zolman et al, 2005; Platta et al, 2007; Williams et al, 2007; Koller et
al, 1999; Kiel et al, 2006; Schlüter et al, 2006). Notwithstanding these differences, it
seems that the basic design of the peroxisomal biogenesis machinery was fairly
conserved throughout evolution.
All peroxisomal matrix and membrane proteins are encoded by nuclear genes
(Lazarow & Fujiki, 1985). After synthesis on cytosolic ribosomes, proteins need to be
targeted to the peroxisome. The first hint which suggested that different machineries
were involved in the targeting of matrix and membrane proteins came from the
observation that in many Zellweger patients (section 1.2.2.) cells possess
peroxisomal “ghosts”. These structures contain all membrane proteins but no matrix
content (Santos et al, 1988b, 1988a). In contrast, in a few Zellweger patients no
peroxisomal ghosts could be detected in their cells, suggesting a defect in
peroxisomal membrane biogenesis. The observation of these two distinct phenotypes
pointed for two separated protein import pathways in peroxisomal biogenesis: one for
peroxisomal matrix proteins and another for membrane proteins.
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Details on these two protein targeting pathways will be presented in sections
1.3.1. and 1.3.3. Peroxisome proliferation will be briefly described in section 1.3.2.
Table 4. Proteins involved in peroxisome biogenesis: features and functions.
PEX protein Localization Organism Functions and properties
Matrix protein
import
PEX5 Cyt / Memb M, P, F, Y PTS1 and PTS2 targeting; IDD, TPRs
PEX7 Cyt / Memb M, P, F, Y PTS2 targeting; adaptor protein; WD repeats
PEX18 Cyt / Memb Y PTS2 targeting
PEX20 Cyt / Memb F, Y PTS2 targeting
PEX21 Cyt / Memb Y PTS2 targeting
PEX13 Memb M, P, F, Y SH3
PEX14 Memb M, P, F, Y Coiled-coil
PEX17 Memb Y Coiled-coil
PEX33
(PEX14/17) Memb F Coiled-coil
PEX8 Matrix/ Memb F, Y
PEX2 Memb M, P, F, Y E3; RING zing-binding domain
PEX10 Memb M, P, F, Y E3; RING zing-binding domain
PEX12 Memb M, P, F, Y E3; RING zing-binding domain
PEX1 Cyt / Memb M, P, F, Y Receptor export; AAA ATPase
PEX6 Cyt / Memb M, P, F, Y Receptor export; AAA ATPase
PEX15 Memb F, Y PEX1/PEX6 membrane anchor
PEX26 Memb M, F, Y PEX1/PEX6 membrane anchor
APEM9 Memb P PEX1/PEX6 membrane anchor
AWP1 Cyt M Adaptor protein; A20 and AN1 zinc finger domains
PEX4 Memb/Cyt P, F, Y E2
PEX22 Memb P, F, Y PEX4 membrane anchor
E2D1/2/3 Cyt M E2
UBP15 Memb/Cyt Sc DUB
USP9X Cyt M DUB
Membrane
protein import
PEX3 Memb M, P, F, Y
PEX16 Memb M, P, F, Y
PEX19 Cyt / Memb M, P, F, Y PMP targeting; Farnesylation motif
Proliferation and
inheritance
PEX11 Memb M, P, F, Y
PEX23 Memb F, Y Dysferlin
PEX24 Memb F, Y
PEX25 Memb Y
PEX27 Memb Sc
PEX28 Memb Sc
PEX29 Memb Y
PEX30 Memb Sc Dysferlin
PEX31 Memb Sc Dysferlin
PEX32 Memb Y Dysferlin
PEX34 Memb Sc
Abbreviations: Cyt, cytosol; Memb, membrane; M, mammals; P, plants; F, fungi; Y, yeast; Sc, S.
cerevisiae; PTS1, peroxisomal targeting signal 1; PTS2, peroxisomal targeting signal 2; IDD, intrinsic
disordered domain; TPRs, tetratricopeptide repeats; WD, Tryptophan-aspartate repeat; SH3, Src
homology 3; RING, really interesting new gene; E3, ubiquitin ligase; Ub, ubiquitin; AAA, ATPases
associated with diverse cellular activities; E2, ubiquitin-conjugation enzyme; DUB, desubiquitinase;
PMP, peroxisomal membrane protein.
1.3.1. Peroxisomal membrane biogenesis
The import of peroxisomal membrane proteins (PMPs) is, in parallel with the
origin of the peroxisomal membrane, a very controversial issue. Depending on the
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different views concerning the formation of the organelle, several models of PMP
translation and sorting have been proposed (Beevers, 1979; Fujiki et al, 1984;
Rachubinski et al, 1984; Lazarow & Fujiki, 1985; Purdue & Lazarow, 2001; Dimitrov et
al, 2013). It is generally accepted that peroxisomes can be originated both by growth
and division, as autonomous organelles, as well as, at least under certain
circumstances, by de novo formation via the ER. However, the physiological
relevance of the de novo formation and the contribution of each of the pathways for
the peroxisome biogenesis is still controversial and unknown (Motley & Hettema,
2007; Nagotu et al, 2008; Kim et al, 2006; van der Zand et al, 2012).
So far, three proteins have been identified as the key components of the
membrane biogenesis machinery, namely PEX3, PEX19 and, in mammals, also
PEX16 (Fujiki et al, 2006; Honsho et al, 2002). Deletion of the genes encoding these
proteins results in total loss of peroxisomal structures, suggesting that they play a key
role in the organelle formation (South & Gould, 1999; Matsuzono et al, 1999; Hettema
et al, 2000; Shimozawa et al, 2000; Muntau et al, 2000).
Since PEX19 is present in all peroxisome-containing organisms, displays a
dual peroxisomal/cytosolic localization and has the ability to interact with most PMPs,
it has been suggested that this protein is a shuttling receptor for PMPs (Sacksteder et
al, 2000; Götte et al, 1998; Snyder et al, 1999; Jones et al, 2004; Fransen et al, 2001;
Shibata et al, 2004; Fransen et al, 2005; Halbach et al, 2006; Matsuzono et al, 2006).
According to this idea, PEX19 recognizes newly synthesized PMPs in the cytosol and
transports them to the peroxisome membrane. PEX19 interacts directly with PMPs via
their membrane peroxisomal targeting signal (mPTS) (Sacksteder et al, 2000;
Halbach et al, 2006; Van Ael & Fransen, 2006; Yernaux et al, 2006; Rottensteiner et
al, 2004; Saveria et al, 2007). These are small weakly conserved protein domains,
frequently comprising a cluster of basic residues predicted to form an α-helix,
adjacent to one or more transmembrane segments (Dyer et al, 1996; Baerends et al,
2000; Honsho & Fujiki, 2001; Jones et al, 2001; Wang et al, 2001; Rottensteiner et al,
2004). PEX19 was suggested to also act as a chaperone, preventing aggregation and
degradation of the newly synthesized PMPs, probably by shielding their hydrophobic
protein surfaces (Jones et al, 2004). Accordingly, it was demonstrated that PEX19
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binds PMPs during or immediately after translation, and escorts them to the
peroxisomal membrane, where it interacts with the docking protein, PEX3 (Götte et al,
1998; Fang et al, 2004; Hoepfner et al, 2005; Muntau et al, 2003; Pinto et al, 2006). In
agreement, cargo-loaded PEX19 displays a much higher affinity for PEX3 than
PEX19 alone (Pinto et al, 2006). The interaction of the PEX19-PMP protein complex
with PEX3 ultimately results in the insertion of the PMP into the organelle membrane,
without ATP consumption (Diestelkötter & Just, 1993; Pinto et al, 2006). Interestingly,
it was reported that the cytosolic domain of PEX3 has the capacity to oscillate
between a lipid-free and lipid-bound state, a process that seems to be modulated by
PEX19 (Pinto et al, 2009). This property is behind a model proposing that this domain
triggers the dissociation of the PEX19-PMP complex and participates in the insertion
of the PMP into the organelle membrane (Pinto et al, 2009). PEX16 is an integral
membrane protein, whose function is still unknown. In mammalian cells, it was
proposed it could function either as a receptor, providing the docking site at the
peroxisomal membrane for PEX3-PEX19 complexes, or as a component of a putative
membrane insertion machinery for PMPs (Kim et al, 2006; Matsuzaki & Fujiki, 2008).
Surprisingly, although PEX16 is essential for mammalian peroxisome biogenesis, no
PEX16 ortholog has been found in yeasts, with the exception of Yarrowia lipolytica.
However, in Y. lipolytica, as well as in Arabidopsis thaliana, PEX16 seems to be
implicated in functions other than membrane biogenesis (Guo et al, 2003; Lin, 1999;
Kim & Mullen, 2013).
How the lipid components of the peroxisomal membrane are recruited to the
peroxisomal membrane is still poorly understood, but considering that: 1) high
resolution images obtained by electron microscopy demonstrate the existence of
close physical interactions between peroxisomes and the ER (Rosenberger et al,
2009; Binns et al, 2006; Toulmay & Prinz, 2011; Elbaz & Schuldiner, 2011); 2) the
peroxisomal membrane consists mainly of phosphatidylcholine (PC) and
phosphatidylethanolamine (PE), resembling that of the ER (Fujiki et al, 1982); and 3)
most of the enzymes involved in the synthesis of polar lipids are localized in the ER
and not in peroxisomes (reviewed in (Gibellini & Smith, 2010)), it is commonly
accepted that the ER provides the lipids for the formation of the peroxisomal
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membrane. Two models of lipid trafficking have been proposed: 1) employment of
specialized vesicles (Lazarow & Fujiki, 1985; Raychaudhuri & Prinz, 2008), or 2)
direct transfer from the ER to peroxisomes at contact sites between both organelles
(Raychaudhuri & Prinz, 2008). It should be noted that this last mechanism of lipid
transfer has also been suggested to occur between peroxisomes and other
organelles, such as lipid droplets or mitochondria (Rosenberger et al, 2009).
1.3.2. Peroxisome proliferation
Peroxisomes are highly dynamic organelles that have the remarkable
capacity to adjust their number, size and enzyme content in response to
developmental, environmental, and metabolic stimuli. In the last years several
components of the peroxisome elongation and division machinery have been
identified in mammals, yeast and plants (Fagarasanu et al, 2007; Lingard et al, 2008;
Schrader & Fahimi, 2006; Thoms & Erdmann, 2005; Orth et al, 2007; Schrader, 1998;
Passreiter et al, 1998; Erdmann & Blobel, 1995; Marshall et al, 1995).
Peroxisome proliferation in mammals, involves three isoforms of PEX11:
PEX11α, PEX11β and PEX11γ (Li et al, 2002a, 2002b; Tanaka et al, 2003; Schrader,
1998). This conserved peroxin has a membrane remodeling activity, being able to
deform and elongate the peroxisomal membrane (Lingard & Trelease, 2006; Li &
Gould, 2002; Rottensteiner et al, 2003; Opaliński et al, 2011a, 2011b). It was
observed that an N-terminal amphipathic helix of PEX11 interacts with liposomes that
have a lipid composition resembling that of the peroxisomal membrane, inducing the
membrane bending (Opaliński et al, 2011a). Along with this role in the reorganization
of the peroxisomal membrane before fission (Schrader, 1998; Delille et al, 2010,
2011; Cepińska et al, 2011), PEX11 is also involved in the recruitment of the
peroxisomal fission machinery (Li & Gould, 2003; Koch & Brocard, 2012).
In mammals, the scission machinery is shared with mitochondria (Koch et al,
2005; Schrader, 2006; Waterham et al, 2007; Gandre-Babbe & van der Bliek, 2008;
Schrader et al, 2012) and includes two membrane adaptors, Fission1 (FIS1) and the
mitochondrial fission factor (MFF) (Koch et al, 2005; Gandre-Babbe & van der Bliek,
2008; Itoyama et al, 2013), and the dynamin-like GTPase DLP1/Drp1 (Li & Gould,
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2003; Koch et al, 2003, 2004; Tanaka et al, 2006). FIS1 and MFF potentially act as
DLP1-recruiting factors to constriction sites on the peroxisomal membrane (Koch et
al, 2005; Itoyama et al, 2013). DLP1 is a large and self-assembling GTPase that
mediates peroxisome fission through the formation of ring-like structures around
constricted membranes coupled with GTP hydrolysis (Smirnova et al, 2001; Praefcke
& McMahon, 2004).
1.3.3. Import of peroxisomal matrix proteins
Presently, more than fifty different enzymes involved in the different
peroxisomal metabolic pathways (see section 1.1.) have been identified in
mammalian peroxisomes. Correct sorting of peroxisomal matrix proteins to the lumen
of the organelle is ensured by one of two distinct peroxisomal targeting signals (PTS):
a PTS1 or a PTS2 (Purdue & Lazarow, 2001). The vast majority of mammalian
peroxisomal matrix proteins contain a PTS1 and only a small subset holds a PTS2
(Kunze et al, 2011). The PTS1 consists of a conserved tripeptide sequence located at
the C terminus that was first identified in firefly luciferase as S-K-L (Gould et al, 1987).
Later, this sequence was further extended to a broader consensus sequence that
includes variants of the tripeptide [(S/A/C)-(K/R/H)-(L/M)] (Lametschwandtner et al,
1998). For the vast majority of PTS1-containing proteins, the tripeptide is sufficient for
the proper targeting to the peroxisome. However, it was reported that, in some cases,
other residues near the tripeptide are also involved (Brocard & Hartig, 2006;
Lametschwandtner et al, 1998; Neuberger et al, 2003; Chowdhary et al, 2012;
Lingner et al, 2011).
Only a few mammalian matrix proteins (three to four) harbor a PTS2 (Kunze
et al, 2011). The number of PTS2 proteins in different organisms can vary a lot
ranging from none in Caenorhabditis elegans (C. elegans) and in the diatome
Phaeodactylum tricornutum, to a quarter of the total matrix proteins in Arabidopsis
thaliana (A. thaliana) (Gonzalez et al, 2011; Gould et al, 1989; Kunze et al, 2011;
Motley et al, 2000; Reumann et al, 2004, 2009; Lazarow, 2006). The PTS2 was first
identified in rat liver thiolase as a conserved sequence at the N terminus of the
protein (Swinkels et al, 1991; Osumi et al, 1991). Comparison between this thiolase
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and several other PTS2-containing proteins resulted in the establishment of an N-
terminal degenerated nonapeptide consensus sequence: R-(L/V/I/Q)-X2-(L/V/I/H)-
(L/S/G/A)-X-(H/Q)-(L/A) (Petriv et al, 2004). Unlike the PTS1, which is not processed
upon import, the PTS2 is cleaved in the peroxisomal matrix by proteolytic enzymes
present in higher eukaryotes. These proteases have been recently identified in plants
(DEG15) and mammals (Trypsin domain containing 1, TYSND1) (Lazarow, 2006;
Helm et al, 2007; Mizuno et al, 2013; Kurochkin et al, 2007).
Newly synthesized peroxisomal matrix proteins are bound by specific
cytosolic receptors that recognize their PTSs and escort them to the peroxisomal
membrane. In mammals, plants and many other organisms, both PTS1 and PTS2
proteins are transported to the peroxisome by PEX5, the peroxisomal matrix protein
shuttling receptor (Braverman et al, 1998; Dodt & Gould, 1996; Galland et al, 2007;
Otera et al, 1998; Woodward & Bartel, 2005). The interaction between PEX5 and
PTS1 proteins is direct (Figure 2) and is mediated by the PTS1 motif of the cargo
protein on one hand, and the C-terminal tetratricopeptides repeats (TPRs) of PEX5
on the other, although other regions of both proteins are also involved (see also
below) (Terlecky et al, 1995; Gatto et al, 2000; Klein et al, 2001, 2002; van der Klei &
Veenhuis, 2006; Oshima et al, 2008; Freitas et al, 2011).
The interaction between PEX5 and PTS2 proteins is rather different (Figure
2), requiring the participation of another peroxin, PEX7 (Braverman et al, 1998; Otera
et al, 1998; Matsumura et al, 2000; Woodward & Bartel, 2005; Lazarow, 2006;
Galland et al, 2007). Based on a recent structure of a PEX18/PEX7/PTS2 complex, it
is possible that PEX5 also interacts with the PTS2 directly (Pan et al, 2013).
However, either this interaction is only possible in the presence of PEX7 (e.g., due to
conformational alterations) or is too weak to be productive, because PEX7 is
absolutely essential for the targeting of these proteins to the organelle.
PEX7 presents six WD40 repeats which have the capacity to recognize and
bind the PTS2 peptide (Marzioch et al, 1994; Zhang & Lazarow, 1996; Rehling et al,
1996; Elgersma et al, 1998). Unlike in mammals and plants, yeast and fungi PEX7
does not bind PEX5 and use instead species-specific receptors. These receptors are
PEX18 and PEX21, two redundant proteins, in S. cerevisiae, and PEX20 in Y.
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lipolytica, Pichia pastoris, Hansenula polymorpha, and Neurospora crassa (Titorenko
et al, 1998; Purdue et al, 1998; Braverman et al, 1998; Sichting et al, 2003; Otzen et
al, 2005; Woodward & Bartel, 2005; Léon et al, 2006; Lee et al, 2006; Schliebs &
Kunau, 2006; Galland et al, 2007). All these species-specific peroxins display
structural and functional similarities to the N-terminal half of the mammalian PEX5
which include the capacity to interact with PEX7 and PEX14 (see below) (Dodt et al,
2001; Einwächter et al, 2001; Nito et al, 2002; Lazarow, 2006; Schliebs & Kunau,
2006; Galland et al, 2007).
Figure 2. PEX5-mediated targeting of peroxisomal matrix proteins.
In mammals and plants, PEX5 is responsible for both PTS1 and PTS2 targeting. The interaction
between PEX5 and matrix proteins containing a PTS1 is direct, while the PEX5-PTS2 interaction
requires an adaptor protein, PEX7.
It should be pointed out that some peroxisomal matrix proteins do not
possess an obvious PTS for PEX5 recognition but still depend on PEX5 for their
targeting to organelle (Kragler et al, 1993; Peterson et al, 1997; Klein et al, 2002;
Titorenko et al, 2002; Gunkel et al, 2004; Islinger et al, 2009; Galland & Michels,
2010). Different mechanisms to explain how these proteins reach the peroxisomal
matrix have been proposed (van der Klei & Veenhuis, 2006). In the case of Acyl-CoA
oxidase (ACOX1) from S. cerevisiae and Y. lipolytica, it was suggested the existence
of an internal PTS within the protein, away from the carboxyl terminus, that interacts
with the N-terminal half of PEX5 (Klein et al, 2002). The same reasoning has also
been applied for some other non-PTS proteins (Gunkel et al, 2004; Oshima et al,
2008). Alternatively, it has been proposed that proteins lacking a PTS can reach the
organelle by hijacking the peroxisomal sorting pathway, i.e., by binding proteins that
harbor a targeting signal. This is the so-called piggyback import mechanism (Glover
et al, 1994; McNew & Goodman, 1994; van der Klei & Veenhuis, 2006; Islinger et al,
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2009). It should be noted that this kind of mechanism has been considered because
peroxisomes have the capacity to translocate co-factor bound, folded, and possibly
even oligomerized proteins (McNew & Goodman, 1994; Walton et al, 1995; Lee et al,
1997; Titorenko et al, 2002). Nevertheless, the physiological relevance of this type of
import mechanism is still poorly understood and, in fact, has been recently challenged
(Freitas et al, 2011). Indeed, a recent study has shown that PEX5 binds newly
synthesized matrix proteins which are oligomeric in their native state, strongly
inhibiting their oligomerization. It was therefore proposed that PEX5 may be a
chaperone/holdase, preventing premature protein interactions and keeping cargo
proteins in a monomeric near-native conformation (Freitas et al, 2011). Such function
is probably crucial to ensure that proteins that do not expose their PTS1 signals upon
oligomerization can be efficiently targeted to the peroxisome (Freitas et al, 2011).
However, if this is so, then there is no obvious reason to exclude a scenario where all
newly synthesized peroxisomal matrix proteins are bound by PEX5 before they have
the chance to oligomerize.
1.3.3.1. The peroxisomal matrix import receptor PEX5
PEX5 is a central peroxin in the mammalian peroxisomal matrix protein
import pathway. As explained above it is responsible for the recognition and targeting
of all matrix proteins to the organelle.
In mammals, PEX5 has two main isoforms that result from alternative splicing
of the PEX5 transcript: one with 639 amino acids and another with 602 amino acids.
These are called the large and small isoforms of PEX5, respectively (Braverman et al,
1998). The difference between these two proteins is the presence of a PEX7-binding
domain in the large isoform (between amino acids 214-215 of the small isoform) that
allows targeting of PTS2 proteins to the peroxisome by PEX5 (Braverman et al, 1998;
Otera et al, 1998; Dodt et al, 2001). PEX5 from yeasts and fungi lacks this PEX7-
interacting domain and, consequently, does not transport PTS2 proteins (Purdue et
al, 1998; Einwächter et al, 2001; Stein et al, 2002; Sichting et al, 2003). In plants, two
scenarios can be found, with some species presenting only the larger mRNA of PEX5
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(e.g., in A. thaliana) and others the two mRNAs (e.g., in Oryza sativa) (Hayashi et al,
2005; Woodward & Bartel, 2005; Lee et al, 2006).
Mammalian PEX5 is a 70-kDa protein that can be structurally and functionally
divided into two domains: the N-terminal and the C-terminal halves (Costa-Rodrigues
et al, 2005). Sequence alignment analysis of PEX5 from several species revealed a
high degree of sequence conservation in the C-terminal domain of PEX5 in sharp
contrast to its N-terminal half, which is poorly conserved with the exception of a few
amino acids that comprise the multiple pentapeptide WXXXF/Y repeats, and a highly
conserved cysteine residue that is present in the N terminus of all PEX5 proteins from
all peroxisome-containing organisms (Kragler et al, 1998; Otera et al, 1998; Wimmer
et al, 1998; Schliebs et al, 1999; Gatto & Geisbrecht, 2000; Lee et al, 2006; Bottger et
al, 2000; Costa-Rodrigues et al, 2004).
As depicted in Figure 3, the C-terminal half of PEX5 is a structured domain
that contains two clusters of three TPR motifs, TPRs 1-3 and TPRs 5-7, connected by
a flexible hinge region (TPR4) (Terlecky et al, 1995; Gatto et al, 2000; Gatto &
Geisbrecht, 2000; Klein et al, 2001). The pocket/groove formed between the two
clusters of TPRs constitutes the PTS1-binding site (Gatto & Geisbrecht, 2000;
Stanley et al, 2006). The TPR domain is flexible, alternating between an open “snail”
conformation when unbound, and a locked “ring”-like conformation when interacting
with a PTS1 (Stanley et al, 2006, 2007; Stanley & Wilmanns, 2006). The binding of
PTS1 proteins by PEX5 TPRs is conserved between all species explaining why this
domain is so highly conserved (Brocard et al, 1994; Nuttley et al, 1995; de Walque et
al, 1999; Gatto & Geisbrecht, 2000; Terlecky et al, 1995; Klein et al, 2001).
Unlike its C-terminal region, the N-terminal half of PEX5 is a non-globular
intrinsically disordered domain that harbors the binding motifs for other members of
the Peroxisomal Import Machinery (PIM), such as PEX13 and PEX14, two
components of the Docking Translocation Module (DTM), and, as mentioned before,
PEX7 (Figure 3). In mammals, the diaromatic pentapeptide motifs [WXXX(F/Y)] of the
N-terminal domain of PEX5 are required for the interactions with the components of
the DTM (Azevedo & Schliebs, 2006; Neufeld et al, 2009; Saidowsky et al, 2001;
Gouveia et al, 2000; Otera et al, 2002; Schliebs et al, 1999; Reguenga et al, 2001;
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Bottger et al, 2000). The interaction between PEX5 and PEX14 involves multiple sites
of interaction and it was demonstrated that each of the seven PEX5 diaromatic
pentapeptides bind PEX14 with high affinity (with Kd values in the low nM range),
thus resulting in a very strong interaction (Otera et al, 2002; Saidowsky et al, 2001;
Schliebs et al, 1999). The PEX5-PEX13 interaction also requires the diaromatic
motifs of PEX5 and the C-terminal SH3 motif of PEX13 both in mammals and yeasts
but, in mammals, the N-terminal domain of PEX13 has also been suggested to have
a role in this interaction (Otera et al, 2002; Bottger et al, 2000; Barnett et al, 2000;
Williams & Distel, 2006; Costa-Rodrigues et al, 2005).
Figure 3. Structure of the large isoform of mammalian PEX5.
Schematic diagram of the mammalian PEX5 large isoform structure with the interaction sites for the
components of the PIM. The dark blue bars represent the diaromatic motifs (WxxxF/Y; PEX14 and
PEX13 binding sites). The green box indicate the extra 37 amino acids present in the larger isoform of
PEX5 that harbor the PEX7 binding site (absent in the small isoform of PEX5). The purple boxes
represent the TPR motifs that recognize and bind the PTS1. A crystal structure of these motifs is
represented above (Protein Data Bank accession number 1FCH). Abbreviations: aa, amino acids;
TPR, tetratricopeptide repeats.
Although size exclusion chromatography (SEC) analyses suggested that
PEX5 might be a tetramer, with an apparent molecular mass of approximately 270
kDa, biophysical and biochemical independent approaches demonstrated that PEX5
is actually monomeric in solution, and that the abnormally large Stokes radius
determined by SEC analyses is due to the natively unfolded pre-molten globule-like
character of the N-terminal domain of PEX5 (Schliebs et al, 1999; Costa-Rodrigues et
al, 2005; Carvalho et al, 2006).
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1.3.3.2. The PEX5-mediated peroxisomal protein import pathway
The fact that PEX5 displays in vivo a dual subcellular localization (being
predominantly cytosolic but also peroxisomal) along with its capacity to recognize and
bind cargo proteins, led to the hypothesis that PEX5 is a shuttling receptor for
peroxisomal matrix proteins (McCollum et al, 1993; Van der Leij et al, 1993; Brocard
et al, 1994; Dodt et al, 1995; Wiemer et al, 1995; Fransen et al, 1995; Nuttley et al,
1995; van der Klei et al, 1995; Dodt & Gould, 1996; Elgersma et al, 1996; Wimmer et
al, 1998; de Walque et al, 1999; Jardim et al, 2000). Evidence for this hypothesis
came from the observation that the subcellular distribution of PEX5 can be
manipulated in live cells just by decreasing the temperature of the cell culture or the
intracellular concentration of ATP (Dodt & Gould, 1996). Under these conditions, the
fraction of PEX5 localizing at peroxisomes increases, a situation that can be reverted
by returning the cells to normal conditions. Apparently, PEX5 can undergo multiple
cycles of association and dissociation with the peroxisome.
Our understanding on the PEX5-mediated protein import pathway has
increased dramatically over the last years. Data from protein complex analyses (such
as immunoprecipitations, Blue Native PAGE and sucrose gradients), cell biology
experiments and in vitro import assays have contributed for a more precise and
detailed clarification of how the PIM operates and on the architecture of its
components (Agne et al, 2003; Albertini et al, 2001; Reguenga et al, 2001; Collins et
al, 2000a; Gouveia et al, 2000). So far, all the gathered data points to a dynamic
architecture of the PIM, where several steps of the pathway take place in a large
protein complex in which PEX5 is transiently integrated.
The mammalian PIM comprises ten mammalian peroxins, most of which are
part of one of two functional/structural modules: 1) the DTM, i.e., a membrane-
embedded multisubunit complex that comprises PEX13, PEX14, and the “Really
Interesting New Gene” (RING) peroxins PEX2, PEX10, and PEX12 (Agne et al, 2003;
Reguenga et al, 2001; Oeljeklaus et al, 2012); and 2) the Receptor Export Module
(REM), composed by the two peroxisomal “ATPases associated with diverse cellular
activities” (AAA ATPases), PEX1 and PEX6, together with their peroxisomal
membrane anchor, PEX26 (Matsumoto et al, 2003; Fujiki et al, 2012a) (see Figure 4).
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Finally, the cytosolic receptors, PEX5 and PEX7, complete the list of peroxins
involved in the delivery of newly synthesized proteins to the organelle lumen (Dodt et
al, 1995; Fransen et al, 1995; Braverman et al, 1997). Besides peroxins, the PIM also
includes other proteins involved in ubiquitination/deubiquitination events occurring in
this import pathway. Due to their involvement in other cellular pathways these
proteins are not considered peroxins (Grou et al, 2008, 2012; Miyata et al, 2012).
Using a PEX5-centered in vitro import system, our laboratory has provided
valuable data regarding the mechanistic details of the mammalian PEX5-mediated
protein import pathway. In this system, an organelle suspension is incubated with
radiolabeled PEX5 under different experimental conditions and the behavior of the
radiolabeled protein is monitored by a protease-protection assay. The model
presented in Figure 5 harbors all the data gathered so far regarding this import
pathway.
After binding newly synthesized matrix proteins in the cytosol, PEX5 targets
them to the peroxisomal membrane, where it interacts with members of the DTM.
PEX13 and PEX14 are two integral membrane components of the DTM that have
been shown to interact with the shuttling receptors PEX5 and PEX7, but not with the
cargo proteins, suggesting that they serve as docking sites at the peroxisomal
membrane for the PEX5-cargo complex (Girzalsky et al, 1999; Urquhart et al, 2000;
Bottger et al, 2000; Shimizu et al, 1999; Fransen et al, 1998; Otera et al, 2002;
Azevedo & Schliebs, 2006). As it is further discussed, a role in the cargo translocation
step has also been proposed for PEX14 (Gouveia et al, 2000; Oliveira et al, 2003;
Azevedo & Schliebs, 2006).
After docking at the DTM, PEX5 gets inserted into this protein machinery in a
cargo- and temperature-dependent manner (Costa-Rodrigues et al, 2004; Gouveia et
al, 2003b). At this stage, PEX5 adopts a transmembrane topology exposing a 2-kDa
N-terminal domain into the cytosol while the bulky part of its polypeptide chain faces
the organelle lumen (Gouveia et al, 2003a, 2000). Remarkably, insertion of PEX5 into
the DTM does not require the hydrolysis of cytosolic ATP, a finding that led to the
proposal that the strong protein-protein interactions established by PEX5 on one
hand, and the DTM on the other, are the driving force for the insertion of the receptor-
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cargo complex into the peroxisomal membrane and, perhaps, for the translocation of
the cargo into the organelle matrix (Azevedo et al, 2004; Grou et al, 2009a; Oliveira et
al, 2003). The observation that the N-terminal domain of PEX14, the region that
interacts with the diaromatic motifs of PEX5, is either deeply embedded in the
peroxisomal membrane or even exposed to the peroxisomal matrix, strongly supports
this idea (Saidowsky et al, 2001; Oliveira et al, 2002).
Figure 4. The mammalian peroxisomal import machinery (PIM).
Schematic view of the mammalian import machinery. The components of the PIM can be organized
according to their functions. At the peroxisomal membrane, there are two major multisubunit protein
complexes that belong to the PIM: the Docking/Translocation Module (DTM) that comprises PEX13,
PEX14 and the RING peroxins PEX2, PEX10 and PEX12, and the Receptor Export Module (REM) that
is composed by PEX1 and PEX6, the two peroxisomal AAA ATPases, and their membrane anchor,
PEX26. The shuttling receptors (R), AWP1, elements of the ubiquitin-conjugating cascade (UCC;
ubiquitin (Ub), the Ub-activating enzyme (E1) and the Ub-conjugating enzyme (E2; UbcH5a/b/c)) and
the deubiquitinating enzyme (DUB; USP9X), complete the list of proteins that constitute the PIM. CP,
cargo protein.
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Figure 5. The PEX5-mediated protein import pathway.
Using a PEX5-centered in vitro import system, it was possible to detect and characterize five different
PEX5 populations referred to as stage 0-4, respectively (substages a and b are essentially of
conceptual nature). Several strategies/tools to block this pathway at different steps have been
developed (shown in red) and are also indicated in the figure. Stage 0 – PEX5 is soluble and cargo-
free (PEX5 is completely accessible to an exogenously added protease); Stage 1 – Cytosol-exposed
PEX5-cargo complex (PEX5 is completely accessible to an exogenously added protease); Stage 2 –
PEX5-cargo complex gets inserted into the DTM with PEX5 exposing the N terminus to the cytosol and
most of its polypeptide chain to the organelle lumen (only 2 kDa of the N-terminal domain of PEX5 are
accessible to protease treatment); Stage 3 – DTM embedded PEX5 is monoubiquitinated (PEX5 is
monoubiquitinated and completely resistant to protease treatment); Stage 4 – Monoubiquitinated DTM-
embedded PEX5 is removed from the membrane back to the cytosol, in an ATP-dependent manner, by
the two mechanoenzymes, PEX1 and PEX6 (REM) (at this stage, monoubiquitinated PEX5 is
completely protease accessible); Transition of stage 4 to stage 0, i.e., the deubiquitination of soluble
monoubiquitinated PEX5 to restore free soluble PEX5 is achieved by enzymatic (USP9X) and non-
enzymatic (GSH) mechanisms. The step at which the cargo is translocated and released to the
peroxisome matrix is unknown, but it has been suggested to occur between stage 1 and 2, with PEX5
pushing the cargo across the membrane as it gets inserted into the membrane (Gouveia et al, 2003a;
Oliveira et al, 2003; Azevedo et al, 2004). Abbreviations used: 5, PEX5; CP, cargo protein; Ub,
ubiquitin; DTM, Docking/Translocation Module; REM, Receptor Export Module; cyt, cytosol; mat,
matrix; rTPRs, recombinant protein comprising only the PEX5 tetratricopeptide repeats domain; rPEX5,
recombinant PEX5; E1, ubiquitin-activating enzyme; E2, ubiquitin-conjugating enzyme; IAA,
iodoacetamide; C11S/A, PEX5 protein mutated version with the conserved cysteine 11 replaced by a
serine or an alanine residue; GSH, glutathione.
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The interactions established between the DTM and the DTM-embedded
PEX5 are essentially irreversible (Costa-Rodrigues et al, 2004), therefore it is not
surprising that the removal of PEX5 from the peroxisomal membrane back to the
cytosol requires energy input. Surprisingly, this energy-dependent process is
preceded by monoubiquitination of PEX5 at a conserved N-terminal cysteine residue1
(position 6 and 11 in yeast and mammals, respectively) (Williams et al, 2007;
Carvalho et al, 2007b). This modification is mandatory for the subsequent step of the
pathway, the ATP-dependent PEX5 removal from the peroxisomal membrane back
into the cytosol, a process catalyzed by the REM (Oliveira et al, 2003; Carvalho et al,
2007b; Platta et al, 2007). These findings provided the explanation for earlier reports
showing that deletion of the first 17 amino acids containing this conserved cysteine
residue as well as its alkylation or mutation to a serine residue, result in PEX5
proteins still able to enter the DTM, but that are no longer substrates for the REM
(Costa-Rodrigues et al, 2004; Carvalho et al, 2007b, 2006).
The finding that mammalian PEX5, like its yeast counterpart, is
monoubiquitinated at the DTM was unexpected at the time because, as stated before
(see section 1.3.), mammals lack PEX4 and PEX22. On one hand, it was now
obvious that the PIM of yeasts and mammals operate using similar principles, despite
significant differences in their protein composition (see Table 4 in section 1.3.). On
the other hand, it was evident that we were still missing components of the
mammalian PIM. Using a peroxisome-dependent PEX5 monoubiquitination assay it
was found that the long-sought mammalian E2 activity co-fractionated with cytosolic
proteins (Grou et al, 2008). In fact, a simple low-speed centrifugation of a postnuclear
supernatant (PNS) was sufficient to separate peroxisomes from the E2 activity
involved in this ubiquitination event indicating that, contrary to yeasts/fungi and
probably plants (Wiebel & Kunau, 1992; Koller et al, 1999; Zolman et al, 2005),
mammalian peroxisomes do not contain a peroxisomal dedicated E2. Purification of
the factor promoting this activity by standard protein purification procedures led to the
1 Note that although ATP is surely needed to activate ubiquitin, we do not consider that the energy
involved in monoubiquitination of PEX5 contributes for its export because the ΔG of the corresponding
transthiolation reaction should be close to 0 kcal/mol (Grou et al, 2009b).
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identification of the multipurpose cytosolic rat E2s, E2D1/2/3 (UbcH5a/b/c in humans)
(Grou et al, 2008; Gonen et al, 1999; Saville et al, 2004).
Considering that three of the five core components of the DTM contain RING
Zn2+-binding domains, which define the largest class of E3 ubiquitin ligases, it was
evident from the very first findings on receptor ubiquitination that these three
peroxins, PEX2, PEX10 and PEX12, should have a role in this event (Liu &
Subramani, 2013; Williams et al, 2008; Kaur et al, 2013; Platta et al, 2009). In line
with this hypothesis, it was reported that the Zn2+-binding domains of these peroxins
have E3 activity in in vitro ubiquitination assays (Williams et al, 2008; Platta et al,
2009; Kaur et al, 2013). Noteworthy, several studies reported that PEX5 can still enter
the DTM in cells lacking these peroxins (Dodt & Gould, 1996; Chang et al, 1999;
Collins et al, 2000b; Agne et al, 2003). Thus, the DTM resembles a multisubunit E3
ligases (e.g., cullin RING ligases) in which substrates are recruited not by the RING
proteins but by other subunits of the protein complex (Grou et al, 2009a; Francisco et
al, 2013).
The mechanistic details of how monoubiquitinated PEX5 is recognized by the
REM are still not entirely understood. In principle, the REM could interact directly with
DTM-embedded monoubiquitinated PEX5 or, alternatively, the recognition could be
mediated by an ubiquitin-binding adaptor protein. Some data supporting this last
possibility was recently reported. Indeed, AWP1 was identified as a protein possibly
involved in the interaction between monoubiquitinated PEX5 and the REM (Miyata et
al, 2012). After dislocation of DTM-embedded monoubiquitinated PEX5 into the
cytosol, PEX5 is deubiquitinated to yield free soluble PEX5. This step probably occurs
very fast in vivo because so far soluble thiol-sensitive monoubiquitinated PEX5
species were never detected (Grou et al, 2009b; Williams et al, 2007). Using an
unbiased biochemical approach, USP9X was identified as the most active
mammalian deubiquitinase (DUB) acting on monoubiquitinated PEX5 (Grou et al,
2012). Interestingly, however, knockdown of USP9X did not result in the cytosolic
accumulation of monoubiquitinated PEX5 as it would be expected if this DUB were
the only factor capable of deubiquitinating PEX5. Three possibilities may explain this
result: 1) the low levels of USP9X still present in the knockdown experiments may be
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sufficient to catalyze PEX5 deubiquitination; 2) less active/redundant DUBs may
deubiquitinate PEX5 in the absence of USP9X; or 3) non-enzymatic mechanisms may
also be involved in the deubiquitination of PEX5 (Grou et al, 2012). Indeed, it was
demonstrated that physiological concentrations of glutathione are sufficient to disrupt
the labile thioester bond linking ubiquitin to PEX5 in only a few minutes (Grou et al,
2009b). Interestingly, DTM-embedded monoubiquitinated PEX5 is protected from
both enzymatic and non-enzymatic deubiquitination mechanisms, thus preventing
futile ubiquitination/deubiquitination cycles at the DTM (Grou et al, 2009b).
Most of the mechanistic data presented above for the PEX5-mediated import
pathway, was obtained using a PEX5-centered in vitro import system. However, this
PEX5-centered model lacks important information concerning the cargo protein,
namely on how and when it is translocated across the peroxisomal membrane. Two
different scenarios have been proposed: 1) the driving force for the protein
translocation could reside in the strong protein-protein interactions established
between PEX5 and components of the DTM, with the translocation of the cargo
occurring as PEX5 gets inserted into the DTM, with no ATP consumption (Gouveia et
al, 2003a; Oliveira et al, 2003; Azevedo et al, 2004); and 2) cargo translocation and
release could be linked to the ubiquitination and export of PEX5 back to the cytosol,
coupling the energy requirements of the receptor monoubiquitination/extraction with
cargo translocation (Williams et al, 2007; Grou et al, 2009a; Schliebs et al, 2010).
Recently, in an attempt to answer these questions, a PTS2-centered in vitro import
system was developed in our laboratory (Alencastre et al, 2009). The data obtained
suggests that translocation of pre-thiolase, one of the 3-4 PTS2 proteins in mammals,
across the peroxisomal membrane occurs before ubiquitination of DTM-embedded
PEX5, probably while the receptor gets inserted into the DTM (Alencastre et al,
2009). However, considering that mammalian PTS2 proteins are targeted to the
peroxisome lumen with the help of the adaptor protein PEX7, and that there are some
data suggesting that this peroxin may enter the organelle matrix together with the
PTS2 proteins, it remains unclear whether the mechanistic data gathered for PTS2
proteins is a general property of the peroxisomal protein import machinery or a unique
feature of the PTS2 import pathway (Swinkels et al, 1991; Kunze et al, 2011;
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Lazarow, 2006; Braverman et al, 1997, 1998; Otera et al, 1998; Nair et al, 2004). The
main aim of the work presented here was to answer this question.
2. AIMS
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AIMS
Our laboratory has been using an in vitro import strategy to dissect the
mechanism of protein translocation across the mammalian peroxisomal membrane.
Currently, our knowledge on the pathway followed by PEX5 during the protein import
process is reasonably detailed. However, the same cannot be stated regarding the
cargo proteins themselves. In an attempt to fill in this gap, the import mechanism of a
PTS2 protein has been recently characterized. It was proposed that translocation of
this protein across the peroxisomal membrane occurs upstream of PEX5
monoubiquitination. Yet, it is still unknown whether this property is a particularity of
the PTS2 sorting pathway or a general property of the peroxisomal protein import
machinery.
The main aim of this work was the development of an in vitro import system
centered on a PTS1 cargo protein so that we could: 1) identify the step(s) at which
the PTS1 cargo protein is moved from the cytosolic side of the peroxisomal
membrane into the DTM; 2) determine the timing of the PTS1 cargo protein release
from the DTM into the peroxisomal matrix; and 3) define the energetics of the protein
translocation process.
3. EXPERIMENTAL PROCEDURES
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3.1.Expression and purification of recombinant proteins
The recombinant large isoform of human PEX5 [hereafter simply referred to
as PEX5; (Fransen et al, 1998; Braverman et al, 1998; Costa-Rodrigues et al, 2005)],
proteins comprising amino acid residues 1-324 and 315-639 of PEX5 [ΔC1PEX5 and
TPRs, respectively; (Carvalho et al, 2006)], PEX5 containing the missense mutation
N526K [PEX5(N526K), (Gatto & Geisbrecht, 2000; Dodt et al, 1995; Carvalho et al,
2007a)], TPRs with the missense mutation N526K [TPRs(N526K), numbering of full-
length PEX5; (Carvalho et al, 2007a)], a protein comprising the first 80 amino acid
residues of human PEX14 [NDPEX14; (Carvalho et al, 2006)], PEX19 (Pinto et al,
2006) and a Glutathione S-Transferase-Ubiquitin fusion protein [GST-Ub; (Carvalho
et al, 2007b)] were obtained as previously described.
A mutated PEX5 version possessing an alanine at position 11 was obtained
with the QuikChange Site-Directed Mutagenesis kit (Stratagene), using pQE30-
PEX5 as the template (Costa-Rodrigues et al, 2005) and the primers listed in Table 5
(section 3.10.) previously described (Grou et al, 2009b). Expression in the M15 strain
of Escherichia coli and purification with HIS-Select Nickel Affinity Gel (Sigma) were
performed also as described before (Carvalho et al, 2006).
3.2.Plasmids and synthesis of radiolabeled proteins
The cloning strategy for PEX5 mutated versions possessing a lysine or
alanine residue at position 11 [PEX5(C11K) or PEX5(C11A), respectively] were
described elsewhere (Grou et al, 2009b).
The cDNAs encoding full-length mouse Sterol Carrier Protein x [SCPx; clone
MmCD00313611, PlasmID, Dana Farber/Harvard Cancer Center; (Seedorf et al,
1993)] and full-length human 2,4-Dienoyl-CoA Reductase [DECR2; plasmid pKDN36,
kindly provided by Dr. Marc Fransen (De Nys et al, 2001)] were amplified by PCR
using the primers listed in Table 5, section 3.10. The amplified sequences were
subsequently digested with XbaI and KpnI and cloned into the XbaI/KpnI-digested
pGEM4® vector (Promega), originating pGEM4-SCPx and pGEM4-DECR2,
respectively.
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35S-Labeled proteins were synthesized using the TNT® T7 Quick Coupled
Transcription/Translation System (Promega) in the presence of [35S]methionine
(specific activity >1000 Ci/mmol; PerkinElmer Life Sciences) following the standard
conditions of the manufacturer.
3.3.Preparation of postnuclear supernatants (PNS) from mouse liver
Mouse liver PNS fractions for in vitro assays were prepared from male
C57BL/6J mice with approximately 6 weeks of age. Mice were fasted overnight and
euthanized by cervical dislocation. The livers were quickly removed, minced and
homogenized in ice-cold SEM buffer (0.25 M sucrose, 20 mM MOPS-KOH, pH 7.2, 1
mM EDTA-NaOH, pH 8.0) supplemented with 2 μg/ml N-(trans-epoxysuccinyl)-L-
leucine 4-guanidinobutylamide (E-64). After centrifuging the homogenates twice at
600 x g for 10 min at 4 ºC (SS-34 rotor in a RC5B Sorvall® centrifuge), the resulting
supernatant was aliquoted, frozen in liquid nitrogen and stored at -70 ºC. Protein
content of PNS fractions was determined using the Bradford method and rabbit
immunoglobulins as protein standards.
3.4. In vitro import experiments:
3.4.1. 35S-Scpx in vitro peroxisomal import assays
In a standard import reaction, 400 μg of mouse liver PNS protein (per 100 μl
reaction) were primed for import by incubation in import buffer (0.25 M sucrose, 50
mM KCl, 20 mM MOPS-KOH, pH 7.2, 3 mM MgCl2, 20 μM methionine, 2 μg/ml E-64)
supplemented with 0.3 mM ATP for 5 min at 37 ºC, as described previously (Oliveira
et al, 2003). One microliter of the reticulocyte lysate containing 35S-labeled SCPx was
diluted 1:10 in import buffer and pre-incubated for 15 min at 37 ºC in the presence of
PEX5 (30 nM final concentration). Ten microliters of the diluted lysate were
subsequently added to the PNS in import buffer supplemented with 2 mM glutathione
(GSH), 3 mM ATP and 15 μM of a bovine ubiquitin. The import reaction was allowed
to proceed for 15 min at 37 ºC and, after import, samples were digested with 400
μg/ml of Proteinase K (PK) for 40 min on ice. Protease was inactivated with 500 μg/ml
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of phenylmethylsulfonyl fluoride (PMSF) and incubated for 3 min on ice. The
organelle suspensions were diluted to 1 ml with SEMK (SEM buffer containing 80 mM
KCl) and organelles were isolated by centrifugation (16,000 x g, 20 min, 4 ºC). Protein
in the samples was precipitated with 10% (w/v) trichloroacetic acid (TCA) for 30 min
on ice. After centrifugation (16,000 x g, 15 min, 4 ºC), the precipitated protein was
washed with acetone, subjected to SDS-PAGE and transferred onto a nitrocellulose
membrane. The membranes were stained with Ponceau S, exposed to an x-ray film
and afterwards probed with the relevant antibodies.
When specified, the standard protocol was modified and the following
alterations were performed:
1) In experiments aiming at analyzing the effect of pre-incubating SCPx with
recombinant PEX5 in its import efficiency, the reticulocyte lysate containing 35S-SCPx
was also diluted in import buffer and pre-incubated for 15 min at 37 ºC in the absence
of PEX5. After the addition of the diluted lysate to a PNS, the same amount of
recombinant PEX5 (30 nM, see above) was added, and the import reaction performed
under the same conditions.
2) In experiments evaluating the specificity of the in vitro import system using
different recombinant proteins, the pre-incubation step was altered: one microliter of
the reticulocyte lysate containing 35S-labeled SCPx was diluted 1:10 in import buffer
and pre-incubated for 15 min at 37 ºC in the presence of one or more of the following
recombinant proteins: PEX5 or PEX5(N526K) or PEX5(C11A) (30 nM final
concentration), TPRs or TPRs(N526K) (10 μM final concentration), and NDPEX14 or
PEX19 (20 μM final concentration).
3) When evaluating the energetic requirements of 35S-SCPx import, the diluted
lysate added to the PNS was supplemented with 2 mM glutathione and, where
indicated, ATP (3 mM) or AMP-PNP (3 mM), and bovine ubiquitin (15 μM). In the
apyrase experiments, both the diluted lysate and the PNS in import buffer were
incubated at 37 ºC with apyrase (20 units/ml, Grade VII, Sigma) for 5 and 2 min,
respectively, before starting the import assay. The import reaction was incubated for
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just 7 min to minimize differences induced by the time-dependent occupation of the
DTM by PEX5 (Alencastre et al, 2009).
3.4.2. 35S-PEX5 in vitro import assays
Control experiments for the AMP-PNP and apyrase treatments in the PEX5-
mediated import pathway were performed as follows. For the AMP-PNP experiment,
the reticulocyte lysate containing 35S-labeled PEX5(C11K) was diluted 1:10 in import
buffer and added to 400 μg of PNS protein that had been primed for import. Import
assays contained 2 mM of GSH, 15 μM of bovine ubiquitin, 3 μM of ubiquitin
aldehyde (Ubal) and either 3 mM of ATP or AMP-PNP. After 7 min at 37 ºC, the
import reactions were centrifuged to separate organelles from the soluble phase. Both
fractions were analyzed by SDS-PAGE/Western-blotting. In the apyrase assay, the
reticulocyte lysate containing 35S-labeled PEX5(C11K) was diluted 1:10 in import
buffer and halved. Half of the sample was incubated in the absence of apyrase and
added to a primed PNS in ATP-containing import buffer. The second half of the
diluted lysate was treated with apyrase (20 units/ml final concentration, for 5 min at 37
ºC) and added to an apyrase-treated PNS (20 units/ml final concentration, for 2 min at
37 ºC). Import reactions were supplemented with 2 mM of GSH and 15 μM of GST-
Ub and incubated at 37 ºC for 7 min. The organelles were then isolated by
centrifugation and samples were processed as described above.
3.5.Sucrose gradient centrifugation analyses of proteins
For the sucrose gradient centrifugation analyses, 10 μl of SCPx lysate were
incubated with 25 μg of recombinant PEX5 in 200 μl of a buffer containing 50 mM
Tris-HCl, pH 8.0, 150 mM NaCl, 1 mM EDTA-NaOH, pH 8.0, and 1 mM DTT or with
buffer alone. After incubation for 10 min at room temperature, 30 μg of each of the
following internal sedimentation coefficient standards were added to the samples:
ovalbumin (3.6 S), bovine serum albumin (4.3 S) and aldolase (7.4 S). Protein
mixtures were then loaded onto the top of a continuous 5-20% (w/v) sucrose gradient
in the same buffer. After centrifugation at 247,000 x g for 29 h at 4 °C in a SW41
swing-out rotor (Beckman), 13 equal fractions were collected from the bottom of the
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gradient. One hundred and fifty microliters of each fraction were precipitated with TCA
precipitation and analyzed by SDS-PAGE as described above.
3.6. 35S-SCPx susceptibility to Proteinase K (PK) digestion
To evaluate 35S-SCPx susceptibility to PK digestion several experiments were
performed:
1) One microliter of the reticulocyte lysate containing 35S-labeled SCPx was
diluted 1:10 in import buffer and pre-incubated for 15 min at 37 ºC in the absence or
presence of PEX5 (30 nM final concentration). Both samples were then treated with
400 μg/ml of PK and incubated on ice for 40 min. After protease inactivation, samples
were precipitated with 10% (w/v) TCA.
2) Five microliters of the reticulocyte lysate containing 35S-SCPx were mixed with
2 mg of PNS in import buffer containing or not 1% (w/v) Triton X-100 (TX-100).
Aliquots containing 400 μg of PNS were subsequently treated with different amounts
of PK (0 to 500 μg/ml). Protease was inactivated with 500 μg/ml of PMSF and
incubated for 3 min on ice. Samples were subsequently precipitated with 10% (w/v)
TCA.
3) After a standard in vitro import reaction, organelles were isolated by
centrifugation, resuspended in import buffer and subjected to PK digestion (50 μg/ml),
in the absence or presence of 1% (w/v) TX-100. After protease inactivation with 50
μg/ml of PMSF, samples were subjected to TCA precipitation.
3.7.Sub-fractionation of peroxisomes
Sub-fractionation of peroxisome proteins was performed as follows. Protease-
treated organelles were isolated by centrifugation and resuspended in 1 ml of SEM
buffer supplemented with 1:500 (v/v) PMSF and mammalian protease inhibitor
cocktail (Sigma), and 2 mM DTT. After sonication, half of the sample was kept on ice,
while the other half was separated into membrane and soluble fractions by
centrifugation for 45 min at 135,000 x g. Samples were subjected to precipitation with
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10% (w/v) of TCA and subjected to SDS-PAGE/Western-blotting. After exposing to an
X-ray film, membranes were probed with several antibodies.
3.8.Density gradient centrifugation of import reactions
For the Nycodenz gradient centrifugation analysis of import reactions, a 4-fold
scale-up of the standard import reaction was used. After PK treatment, the complete
import mixture was diluted to 1.5 ml with SEM buffer and applied onto a Nycodenz
step gradient. The Nycodenz step gradient was used as previously described for rat
liver with minor modifications (Pinto et al, 2006). The Nycodenz step gradient
consisted in 4 steps: 1.5 ml of 45% (w/v), 7 ml of 28% (w/v), 2 ml of 25% (w/v), and 2
ml of 20% (w/v) Nycodenz in 5 mM MOPS-KOH, pH 7.2, and 1 mM EDTA-NaOH, pH
8.0. After centrifugation at 59,000 x g for 3 h at 4 ºC in a vertical rotor
(STEPSAVERTM 65V13, Sorvall®), 14 equal fractions were collected from the bottom
of the gradient. Two hundred and fifty microliters of each fraction were precipitated
with TCA, subjected to SDS-PAGE and transferred onto a nitrocellulose membrane.
The membrane was stained with Ponceau S and exposed to an x-ray film.
Afterwards, it was probed with the relevant antibodies.
3.9.Antibodies
The antibodies directed to SCPx (19182-1-AP; ProteinTechTM), catalase
(C0979; Sigma), KDEL (ab12223; Abcam), and cytochrome c (556433; BD
PharmingenTM) were purchased. The antibody directed to PEX14 was described
before (Reguenga et al, 2001). Rabbit and mouse antibodies were detected using
goat alkaline phosphatase-conjugated anti-rabbit or anti-mouse antibodies (A9919
and A2429, respectively; Sigma) or goat anti-mouse IgG-HRP (sc-2005; Santa Cruz
Biotechnology).
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3.10. Primers list
Table. 5. List of oligonucleotides used for cloning in this work
construct Primers Sequence
pQE30-
PEX5(C11A)
P5C11A Fw 5’–GGTGGAGGCCGAAGCCGGGGGTGCCAAC–3’
P5C11A Rv 5’–GTTGGCACCCCCGGCTTCGGCCTCCACC–3’
pGEM4-SCPx
SCPx_Fw 5’–GCGCCGTCTAGAGCCACCATGCCTTCTGTCGCTTTG–3’
SCPx_Rev 5’–GCCGGCGGTACCTCACAGCTTAGCTTTGCCC–3’
pGEM4-
DECR2
DECR2_Fw 5’–GATAATTCTAGAGCCACCATGGCCCAGCCGC–3’
DECR2_Rev 5’–CGCCGTGGTACCCTAGAGCTTAGCAGAGAAGGA–3’
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4.1.Development of an in vitro import system centered on a PTS1 protein.
An in vitro import system has been used in our laboratory to study how the
peroxisomal import machinery operates. Experimentally this in vitro strategy
comprises three steps. First, an in vitro transcription/translation kit, usually a rabbit
reticulocyte lysate, is used to synthesize a 35S-labeled reporter protein. In the second
step, the reporter protein is incubated under appropriate experimental conditions with
a PNS, i.e., a subcellular fraction that contains peroxisomes and all the cytosolic
components involved in the PEX5-mediated protein import pathway. Finally, the
organelle suspension is subjected to a protease-protection assay, i.e., the import
reaction is treated with a large amount of a non-specific protease (e.g., proteinase K)
to degrade the fraction of non-imported (thus accessible) reporter protein while
preserving the fraction that was imported into the organelles. While this strategy
works quite well when the reporter protein is PEX5 itself (Gouveia et al, 2003a; Grou
et al, 2009b; Miyata & Fujiki, 2005), the import yields obtained using peroxisomal
matrix proteins as reporters are generally poor. As explained in a previous work
(Alencastre et al, 2009), a major limitation rises from the fact that PNS contains large
amounts of soluble PTS1 proteins that have leaked from peroxisomes during tissue
homogenization (Imanaka et al, 1987; Alexson et al, 1985). Since the PTS1 is not
cleaved upon import (Purdue & Lazarow, 2001), these soluble proteins compete with
the 35S-labeled reporter protein for PEX5 binding, thus resulting in low import yields.
Addition of recombinant PEX5 to in vitro import reactions to minimize this competition
problem results in import yields that are still modest (see below; and unpublished
results). Probably, the addition of the recombinant protein to the import reaction
results in the increase of complexes comprising PEX5 and endogenous PTS1
proteins, producing a new competition problem at the DTM.
To overcome these problems, a new strategy was developed: the incubation
of a radiolabeled PTS1 protein with recombinant PEX5 prior to the in vitro import
reaction. Two main reasonings were behind this strategy: 1) pre-incubation could
allow the reporter protein to form a complex with PEX5 with no competition from the
PTS1 proteins present in the PNS, thus providing a kinetic advantage to the reporter
protein in the subsequent import reaction; and, 2) since in our in vitro assays small
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amounts of the reticulocyte lysate containing the reporter protein are used, the
amount of recombinant PEX5 that would be carried over into the import reactions
would also be small, avoiding the competition problem at the DTM referred to above.
Indeed, the use of this strategy resulted in a remarkable improvement of the in vitro
import yields of some PTS1 proteins.
One of these proteins is Sterol Carrier Protein x (SCPx), a peroxisomal matrix
protein that contains a canonical PTS1 and participates in the last step of the
peroxisomal β-oxidation of fatty acids (review in (Gallegos et al, 2001)). SCPx is the
only peroxisomal thiolase of the β-oxidation pathway capable of catalyzing the
thiolytic cleavage of branched-chain fatty acids (Wanders et al, 1997; Atshaves et al,
2007). Its importance in human health is underscored by the existence of a SCPx
deficiency that leads to dystonia, motor neuropathy and advanced
leukoencephalopathy (Ferdinandusse et al, 2006). SCPx is a 59-kDa protein,
homodimeric in its native state, which can be structurally divided into two domains: an
amino-terminal thiolase and a carboxy-terminal sterol carrier protein-2 (SCP2)
(Antonenkov et al, 2000; Seedorf et al, 1994). In vivo, SCPx is partially cleaved in the
peroxisomal matrix, originating two proteins with different activities: a 46-kDa
enzymatically active branched-chain fatty acid thiolase, and a 13-kDa SCP2 known to
bind phospholipids, fatty acids, and fatty-acyl-CoA with high affinity and supposed to
participate in lipid traffic, signaling, and metabolism (Ossendorp et al, 1996; Wirtz,
1997; Gallegos et al, 2001; Antonenkov et al, 1997; Otera et al, 2001; Seedorf et al,
1994; Schroeder et al, 2007). Recently, the peroxisomal processing protease
TYSND1 was identified as the peptidase cleaving
SCPx (as well as ACOX1 and PTS2 proteins) (Kurochkin et al, 2007; Mizuno et al,
2013).
As shown in Figure 6, when radiolabeled SCPx was pre-incubated with
recombinant PEX5 before the in vitro import reaction, the amounts of protease-
protected 35S-SCPx obtained in the import assay were dramatically improved
(compare lanes 3 and 4). It is important to note that the two import reactions shown in
Figure 6 are chemically identical and differ solely in the step of the protocol where
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recombinant PEX5 was added. The huge increase in the in vitro import yield of 35S-
SCPx obtained using this strategy is probably due to the formation of a complex
between PEX5 and SCPx, as explained above. Indeed, upon sucrose gradient
centrifugation (Figure 7), it is possible to observe that when 35S-SCPx is pre-
incubated with PEX5, the sedimentation coefficient of 35S-SCPx changes: in the
absence of PEX5, 35S-SCPx sediments mainly in fraction 4, above bovine serum
albumin (BSA) (fraction 5), whereas in the presence of PEX5, 35S-SCPx peaks
instead below BSA, in fractions 5-6.
Figure 6. In vitro import efficiency of 35S-SCPx can be dramatically improved by pre-incubation
with recombinant PEX5.
Two chemically identical import reactions were assembled, differing solely in the step of the protocol
where recombinant PEX5 was added. In one reaction (lane 3), 35S-SCPx was pre-incubated in the
absence of PEX5, and added to a PNS in ATP-containing import buffer. After addition of recombinant
PEX5, the reaction was incubated for 15 min at 37 ºC. In the other reaction (lane 4), 35S-SCPx was
pre-incubated with recombinant PEX5, added to a PNS in the same buffer and incubated under the
same conditions. Proteinase K-treated organelles were then subjected to SDS-PAGE/Western-
blotting/autoradiography. Lanes 1 and 2 contain 5% of the pre-incubated 35S-SCPx proteins used in the
assays shown in lanes 3 and 4, respectively. The autoradiograph (upper panel) and the Ponceau S-
stained membrane (lower panel) are shown. Numbers to the left indicate the molecular masses of
protein standards in kDa.
It is important to note that when radiolabeled SCPx is incubated in the
absence or presence of recombinant PEX5 and subjected to PK digestion, no
radiolabeled SCPx can be detected (Figure 8A), indicating that 35S-SCPx is highly
susceptible to PK, a property that is not altered by the presence of recombinant
PEX5. Similarly, and in contrast to the endogenous protein, when radiolabeled SCPx
is simply mixed with PNS on ice, and treated with increasing amounts of PK, no
protease-resistant 35S-SCPx can be observed (Figure 8B), suggesting that its
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susceptibility to PK is not affected by the presence of organelles. Furthermore, in the
presence of a mild detergent such as TX-100, both radiolabeled SCPx and
endogenous SCPx are degraded by PK, suggesting that the two proteins are
intrinsically susceptible to the protease.
Figure 7. In vitro synthesized 35S-SCPx interacts with PEX5.
35S-SCPx was pre-incubated for 30 min at room temperature in the absence (upper panels) or
presence (lower panels) of 1 μM recombinant PEX5. After adding a mixture of protein standards, the
samples were subjected to sucrose gradient centrifugation. After fractionation, equivalent aliquots were
subjected to SDS-PAGE/Western-blotting. Note that the sedimentation coefficient of 35S-SCPx
increases in the presence of PEX5, indicating that the two proteins interact. Autoradiographs and the
Ponceau S-stained membranes are shown. Protein standards used were: ovalbumin (Ova; 45 kDa),
bovine serum albumin (BSA; 66 kDa) and aldolase (Ald; 140 kDa).
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Figure 8. 35S-SCPx is highly susceptible to proteinase K (PK).
A) 35S-SCPx incubated in the absence or presence of recombinant PEX5 was treated with PK as
indicated. After inactivation of the protease, the samples were subjected to TCA precipitation, and
analyzed by SDS-PAGE/Western-blotting. An autoradiograph (upper panel) and the corresponding
Ponceau S-stained membrane (lower panel) are shown. B) Five microliters of 35S-SCPx were mixed
with 2 mg of PNS in import buffer containing or not 1% (w/v) TX-100, as indicated. Aliquots containing
400 μg of PNS were then treated with the indicated amounts of PK and processed as above. The
membranes were exposed to an x-ray film (upper panels) and afterwards probed with an anti-SCPx
antibody to detect endogenous SCPx (lower panels). Numbers to the left indicate the molecular
masses of protein standards in kDa.
If the acquisition of a protease-protected status by SCPx in import assays
really reflects its import into peroxisomes, then protease treatment in the presence of
detergents of organelles containing imported 35S-SCPx, should result in the
proteolysis of the radiolabeled protein. Indeed, as shown in Figure 9, the protease-
resistant status of imported 35S-SCPx vanishes in the presence of a detergent (upper
panel). This result thus suggests that the protease-resistant status of imported SCPx
derives from a protection effect exerted by a lipid membrane.
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Figure 9. Imported 35S-SCPx is protected from Proteinase K (PK) degradation by a lipid
membrane.
Organelles from an in vitro import reaction were resuspended in import buffer and treated with PK in
the absence (lane 2) or presence of TX-100 (lane 3). After protease inactivation and TCA precipitation,
samples were analyzed by SDS-PAGE and Western-blotting/autoradiograhy. The behaviors of
endogenous SCPx and catalase (Cat) are shown. Please note that the behavior of endogenous
catalase, used here as a control, is different, because mouse liver catalase is quite resistant to this
protease. Lane 1 contains 5% of the radiolabeled SCPx used in the assays. Numbers to the left
indicate the molecular masses of protein standards in kDa.
4.1.1. Validation of the PTS1-centered in vitro import system developed
Several experiments were performed to characterize the properties and the
specificity of this in vitro import system as well as to confirm that the organelle
targeted by 35S-SCPx is indeed the peroxisome.
We first looked at basic aspects of SCPx import, namely its time- and
temperature-dependence. As shown is Figure 10A, the amount of organelle-
associated protease-resistant 35S-SCPx increases over time. In vitro import of
radiolabeled SCPx is also temperature-dependent (see Figure 10B). At low
temperatures the import efficiencies are significantly lower than those obtained at 26
ºC or 37 ºC. This result is in perfect agreement with the previous data obtained for
PEX5 ((Costa-Rodrigues et al, 2004); see also section 4.3.).
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If the acquisition of an organelle-associated protease-protected status of 35S-
SCPx is indeed related to the PEX5-mediated import process of SCPx, then replacing
PEX5 by PEX5(N526K), a PEX5 mutant protein that is unable to efficiently bind PTS1
proteins (Dodt et al, 1995; Gatto & Geisbrecht, 2000; Carvalho et al, 2007a), should
yield a negative result in our import assays. Indeed, as shown in Figure 11, this was
exactly the result obtained (Figure 11, compare lanes 3 and 4). A similar negative
result was obtained when 35S-SCPx was pre-incubated with both recombinant PEX5
and a molar excess of a protein comprising the PTS1-binding domain of PEX5 (TPRs;
Figure 11, lane 5). The latter protein can still bind PTS1 proteins efficiently but lacks
the N-terminal domain of PEX5 required for a productive interaction with the
peroxisomal DTM (Szilard & Rachubinski, 2000). The inhibitory effect of TPRs
requires its PTS1-binding activity because a mutant version of this protein carrying
the N526K mutation [TPRs(N526K)] does not interfere with the PEX5-mediated
import of radiolabeled SCPx (Figure 11, lane 6). When 35S-SCPx was pre-incubated
with PEX5 plus a recombinant protein comprising the N-terminal domain of PEX14
(NDPEX14), a component of the DTM, no protease-resistant 35S-SCPx was detected
(Figure 11, lane 7). As explained in detail in section 1.3.3.1., this domain of PEX14
binds with high affinity to the so-called diaromatic motifs present in the N-terminal half
of PEX5 (Schliebs et al, 1999) which are essential for the PEX5 interaction with the
DTM (Otera et al, 2002). NDPEX14 may also trigger the release of the cargo protein,
as recently proposed (Freitas et al, 2011). No such effect was obtained when another
recombinant peroxin (PEX19) was used in these experiments (in Figure 11, compare
lanes 7 and 9, respectively). PEX19, as mentioned in section 1.3.1., is involved in a
different pathway of peroxisome biogenesis and was used here simply as a negative
control. Altogether, these in vitro assays show that import of radiolabeled SCPx is
dependent on an available and functional full-length PEX5.
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Figure 10. The in vitro import of 35S-SCPx is time- and temperature-dependent.
A) 35S-SCPx pre-incubated with recombinant PEX5 was subjected to a standard import assay. Aliquots
of the reaction were withdrawn at the indicated time points and treated with PK. After protease
inactivation, organelles were isolated by centrifugation and processed for SDS-PAGE/autoradiography
(upper panel). The Ponceau S-stained membrane is also shown (lower panel). B) Radiolabeled SCPx
pre-incubated with recombinant PEX5 was subjected to import assays in the presence of ATP for 15
min at the indicated temperatures. Samples were processed as described in A). Lane 1 in A) and B)
contains 5% of the radiolabeled SCPx used in the assays. Numbers to the left indicate the molecular
masses of protein standards in kDa.
To confirm that the membrane-bound organelle to which PEX5 targets 35S-
SCPx is in fact the peroxisome, a protease-treated import reaction was loaded onto a
discontinuous Nycodenz gradient and centrifuged. The gradient was subsequently
fractionated and equal aliquots of each fraction were subjected to SDS-
PAGE/Western-blotting and autoradiography. This technique explores the fact that
peroxisomes display a density higher than other organelles present in mouse liver
PNS (Hartl et al, 1985). As shown in Figure 12, most mitochondria and microsomes
are found in fractions 5-10 and 8-11, respectively, as assessed using organelle-
specific antibodies (anti-cytochrome c and anti-KDEL, respectively). Peroxisome
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gradient distribution was assessed using antibodies directed to catalase and
endogenous SCPx. In contrast to mitochondria and microsomes, most peroxisomes
are found in fractions 1-3, near the bottom of the gradient, and represent highly pure
intact peroxisomes (Gouveia et al, 2003a; Pinto et al, 2006). We note that a major
fraction of catalase is also detected at the top of the gradient (fractions 10-13). This
population represents mostly catalase that has leaked from peroxisomes during
preparation of the PNS (Gouveia et al, 2003a; Pinto et al, 2006). Unlike non-
peroxisomal/soluble SCPx, which is proteinase K-sensitive, non-peroxisomal mouse
liver catalase is quite resistant to this protease (see Figure 6, lower panel).
Importantly, the distribution of in vitro imported radiolabeled SCPx parallels the one of
the endogenous mouse liver SCPx, i.e., it is found essentially in fractions 1-3, where
highly pure peroxisomes sediment. Collectively, these data show that 35S-SCPx is
efficiently imported into peroxisomes in vitro.
Figure 11. 35S-SCPx in vitro import depends on the peroxisomal receptor PEX5.
35S-SCPx was pre-incubated in the absence (-) or presence (+) of the indicated recombinant proteins.
Protein mixtures were then subjected to standard import assays and analyzed as described in Figure
10. Lane 1 contains 5% of the radiolabeled SCPx used in the assays. Numbers to the left indicate the
molecular masses of protein standards in kDa.
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Figure 12. Imported 35S-SCPx co-localizes with peroxisomes in a Nycodenz gradient.
A protease-treated import reaction was subjected to Nycodenz gradient centrifugation. The behaviors
of 35S-SCPx, endogenous SCPx, catalase (Cat), cytochrome c (Cyt c; a mitochondrial marker) and two
endoplasmic reticulum proteins (KDEL; recognizes GRP72 and GRP98) are shown. The fraction of
catalase detected at the top of the gradient represents mostly catalase that has leaked from
peroxisomes during PNS preparation. Unlike soluble SCPx, soluble mouse catalase is quite resistant
to proteinase K. Numbers to the left indicate the molecular masses of protein standards in kDa.
Having established the robustness and specificity of this PTS1-centered in
vitro import system, the next aim of this work was to characterize the translocation
mechanism of a PTS1 protein across the peroxisomal membrane.
4.2.Characterization of the translocation mechanism of a PTS1 cargo protein
across the peroxisomal membrane
4.2.1. 35S-SCPx import into peroxisomes does not require cytosolic ATP
hydrolysis or PEX5 monoubiquitination
We know from previous work (Oliveira et al, 2003) that most of the DTMs in a
PNS fraction are occupied by endogenous PEX5. In the absence of ATP, this PEX5
4.    RESULTS
51
population will not be extracted back into the cytosol by the REM and thus the import
yields obtained in these conditions are very low and cannot be compared with those
observed in the presence of ATP. To circumvent this problem, the PNS used in all
experiments described below was subjected to a priming step consisting of a 5 min
incubation in the presence of 0.3 mM ATP. The priming step thus ensures that
regardless of the energetic conditions used in the subsequent import assays, the
number of free DTMs is the same at time 0 of the different assays. Naturally, this
number will decrease over time if the assays are made in the presence of AMP-PNP
or apyrase (see below). However, this effect can be minimized by performing import
assays for a short period of time (i.e., 7 min) (Alencastre et al, 2009).
Taking into account these properties of our in vitro import system, we then
asked whether or not import of SCPx requires hydrolysis of cytosolic ATP. Two
different strategies were used for this purpose. In the first, a PNS that had been
primed for import was incubated with a vast excess (3 mM) of AMP-PNP, before
adding the radiolabeled reporter protein. AMP-PNP is a potent inhibitor of ATPases
that cleave the bond between the β- and γ-phosphate groups of ATP, i.e., that
hydrolyze ATP to ADP. It should be noted that ubiquitination of PEX5 at the DTM still
occurs in the presence of AMP-PNP because the ubiquitin-activating enzyme uses
this ATP analog quite efficiently (Grou et al, 2012; Haas et al, 1983). However, the
export of monoubiquitinated PEX5 from the DTM to the cytosol, a process catalyzed
by the ATPases PEX1/PEX6, is completely blocked by AMP-PNP (Grou et al, 2012).
As shown in Figure 13, the import efficiencies of radiolabeled SCPx in reactions
supplemented with either 3 mM ATP (lane 4) or 3 mM AMP-PNP (lane 5) are
essentially the same. Thus, a 10-fold molar excess of AMP-PNP over ATP does not
result in an inhibition of SCPx import although export of monoubiquitinated PEX5 is
blocked under the same conditions (see Figure 14A, compare lanes 3 and 5), as
expected (Grou et al, 2012).
In the second strategy both 35S-SCPx and the primed PNS were treated with
apyrase, an enzyme that hydrolyzes ATP and other NTPs (Hwang & Schatz, 1989),
before the import reaction. This apyrase treatment did not affect the import efficiency
of radiolabeled SCPx (Figure 13, compare lanes 4 and 6). An in vitro import control
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Figure 13. In vitro import of 35S-SCPx does not require cytosolic ATP hydrolysis or
ubiquitination of PEX5.
35S-SCPx was pre-incubated either in the presence of recombinant PEX5 (lanes 1 and 2) or
PEX5(C11A) (lane 3). An aliquot of the PEX5-containing 35S-SCPx was further treated with apyrase
(lane 2). These samples were then subjected to import assays, as follows: lane 4 – assay containing
ATP and 35S-SCPx pre-incubated with PEX5; lane 5 – the same as in lane 4 but in the presence of
AMP-PNP instead of ATP; lane 6 – assay containing 35S-SCPx pre-incubated with PEX5 and PNS,
both pre-treated with apyrase; lane 7 – import assay containing ATP and 35S-SCPx pre-incubated with
PEX5(C11A); lane 8 – the same as in lane 4 but also containing recombinant NDPEX14. Samples
were processed as described in Figure 10. Lanes 1, 2 and 3 contain 5% of the 35S-SCPx samples used
in the assays. Numbers to the left indicate the molecular masses of protein standards in kDa.
experiment using 35S-PEX5 as the reporter protein, shows that the apyrase treatment
efficiently depletes ATP from the reactions because no ubiquitination of PEX5 is
observed under these conditions (Figure 14B, compare lanes 3 and 4), as described
before (Alencastre et al, 2009). Altogether, these results strongly suggest that import
of radiolabeled SCPx into peroxisomes does not require monoubiquitination of PEX5
or the hydrolysis of cytosolic ATP. Additional data supporting the first of these
conclusions was obtained when radiolabeled SCPx was pre-incubated with a
recombinant mutated version of PEX5, PEX5(C11A). PEX5(C11A) possesses an
alanine at position 11 instead of the conserved cysteine that is required for
monoubiquitination and subsequent export of PEX5. As alanine residues cannot be
ubiquitinated, PEX5(C11A) is an import-competent, but export-incompetent PEX5
protein (Grou et al, 2009b). As shown in Figure 13, albeit non-ubiquitinable,
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PEX5(C11A) is as efficient as PEX5 in promoting the import of the cargo (compare
lanes 4 and 7).
Figure 14. Control experiments showing the effect of AMP-PNP and apyrase on PEX5 export
and monoubiquitination, respectively.
A) Export of monoubiquitinated 35S-PEX5(C11K) (35S-Ub-PEX5(C11K)) is completely blocked by
AMP-PNP. 35S-labeled PEX5(C11K) was subjected to in vitro import reactions containing ubiquitin
aldehyde (Ubal; an inhibitor of deubiquitinases) and either ATP (lanes 2 and 3) or AMP-PNP (lanes 4
and 5). After 7 min at 37 ºC, the import reactions were centrifuged to obtain an organelle pellet (P) and
a supernantant (S) and both fractions were analyzed by SDS-PAGE/Western-blotting. Note that AMP-
PNP allows PEX5(C11K) ubiquitination but not its export into the soluble phase of the import reaction
(Grou et al, 2012). Lane 1 contains 5% of the 35S-labeled PEX5(C11K) used in the assays.
B) Monoubiquitination of 35S-PEX5(C11K) is completely blocked by the apyrase treatment. 35S-
labeled PEX5(C11K) was incubated in the absence (-) or presence (+) of apyrase (lanes 1 and 2,
respectively). The first of these samples (minus apyrase) was subjected to an in vitro import assay in
the presence of ATP (lane 3); the apyrase-treated 35S-labeled PEX5(C11K) was subjected to an import
assay using apyrase-treated PNS (lane 4). Both reactions contained also 15 μM of GST-Ub. The
organelles were then isolated by centrifugation and analyzed by SDS-PAGE/Western-
blotting/autoradiography. Note that GST-Ub is efficiently used by the machinery that monoubiquitinates
PEX5 but, in contrast to ubiquitin, results in a PEX5 species that is not exported from the DTM
(Carvalho et al, 2007b; Grou et al, 2009b). Also, monoubiquitinated PEX5(C11K) is more stable than
monoubiquitinated PEX5 upon SDS-PAGE. This property increases the sensitivity of the ubiquitination
assays (Grou et al, 2009b). Lanes 1 and 2 contain 5% of the 35S-labeled PEX5(C11K) used in the
assays.
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4.2.2. 35S-DECR2 is also imported into peroxisomes in a PEX5
monoubiquitination- and cytosolic ATP-independent manner
The results above strongly suggest that SCPx can be specifically imported to
peroxisomes without requiring cytosolic ATP consumption or PEX5
monoubiquitination. To assess whether this property of SCPx import can be extended
to other PTS1 proteins, we repeated the experiments described in the previous
section (see section 4.2.1.) but this time using 35S-2,4-Dienoyl-CoA Reductase (35S-
DECR2).
DECR2 is an auxiliary enzyme of the peroxisomal β-oxidation pathway,
necessary for the complete degradation of mono or poly-unsaturated fatty acids with
double bonds (Fransen et al, 1999). This 33-kDa protein is possibly tetrameric in its
native state and contains a canonical PTS1 signal (AKL) (Fransen et al, 1999; Hua et
al, 2012).
As shown in Figure 15, the import efficiencies of radiolabeled DECR2 are
essentially the same in reactions supplemented with either ATP (lane 4) or AMP-PNP
(lane 5). Similarly, when 35S-DECR2 and the primed PNS were treated with apyrase
before the import reaction, the import efficiency of radiolabeled DECR2 was also not
decreased (Figure 15, compare lanes 4 and 6), suggesting that PEX5
monoubiquitination is also not a requirement for the import of this PTS1 protein. This
conclusion was further corroborated in an assay where recombinant PEX5 was
replaced by PEX5(C11A). No differences were detected when comparing the
efficiencies of PEX5 or PEX5(C11A) in the import of DECR2 (Figure 15, compare
lanes 4 and 7).
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Figure 15. In vitro import of 35S-DECR2 does not require cytosolic ATP hydrolysis.
35S-labeled 2,4-dienoyl-CoA reductase (35S-DECR2) was pre-incubated either in the presence of
recombinant PEX5 (lanes 1 and 2) or PEX5(C11A) (lane 3). An aliquot of the PEX5-containing 35S-
DECR2 was further treated with apyrase (lane 2). These samples were then subjected to import
assays, as follows: lane 4 – assay containing ATP and 35S-DECR2 pre-incubated with PEX5; lane 5 –
the same as in lane 4 but in the presence of AMP-PNP instead of ATP; lane 6 – assay containing 35S-
DECR2 pre-incubated with PEX5 and PNS, both pre-treated with apyrase; lane 7 – import assay
containing ATP and 35S-DECR2 pre-incubated with PEX5(C11A); lane 8 – the same as in lane 4 but
also containing recombinant NDPEX14. Samples were processed as described in Figure 10. Lanes 1,
2 and 3 contain 5% of the 35S-DECR2 samples used in the assays. Numbers to the left indicate the
molecular masses of protein standards in kDa.
4.2.3. 35S-SCPx is released into the peroxisomal matrix before PEX5
monoubiquitination
The experiments presented above, indicate that 35S-SCPx acquires a
protease-protected peroxisomal location in a process that requires PEX5, but not its
ubiquitination, nor hydrolysis of cytosolic ATP. However, it remains unclear whether
the protease-protected 35S-SCPx detected in all those experiments represents a
protein that was already translocated into the peroxisomal matrix or a species that is
still associated with the DTM. To clarify this issue, radiolabeled SCPx was pre-
incubated with either PEX5 or PEX5(C11A) and subjected to import assays in the
presence of ATP or AMP-PNP or apyrase, as indicated in Figure 16. After protease
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treatment, the organelles were isolated by centrifugation, disrupted by sonication and
ultracentrifuged to obtain membrane (lanes P) and soluble (lanes S) fractions. The
efficiency of the fractionation procedure was assessed by Western-blotting using
antibodies directed to PEX14 (a peroxisomal intrinsic membrane protein), cytochrome
c (a peripheral membrane mitochondrial protein) and catalase (a soluble peroxisomal
matrix protein). The results obtained show that cytochrome c and PEX14 are mostly
found in the membrane fraction, whereas catalase is almost completely recovered in
the soluble fraction, as expected. Although a major fraction of endogenous SCPx was
found in the soluble fraction, some protein was also recovered in the membrane
pellet. The reason why SCPx and catalase present slightly different behaviors may be
Figure 16. In vitro imported 35S-SCPx behaves as endogenous SCPx upon fractionation of
peroxisomes.
35S-SCPx pre-incubated with the indicated PEX5 proteins was subjected to in vitro import assays under
different energetic conditions, as specified. At the end of the import reaction, the organelles were
treated with PK, isolated by centrifugation, and sonicated. One half of these samples was kept on ice
(lanes T) whereas the other half was ultracentrifuged to obtain membrane (P) and soluble (S) fractions.
Samples were analyzed by SDS-PAGE/Western-blotting/autoradiography. The behaviors of
endogenous SCPx, catalase (Cat), PEX14, and cytochrome c (Cyt c) are also shown. Note that PEX14
is converted into small 16-18 kDa fragments (PEX14’) upon PK treatment (see also (Oliveira et al,
2002)). Numbers to the left indicate the molecular masses of protein standards in kDa.
related to the intrinsic properties of the C-terminal half of SCPx. Indeed, it was
demonstrated that the C-terminal SCP2 domain of SCPx is capable of binding
membrane lipids (Seedorf et al, 1994). Importantly, and regardless of the
experimental conditions used in the import assays, in vitro imported radiolabeled
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SCPx displays exactly the behavior of endogenous SCPx, thus suggesting that it
represents a species that was already translocated into the matrix of the organelle.
4.3.Docking and translocation are different steps of the PEX5-mediated protein
import pathway
The data presented thus far suggest that import and translocation of
radiolabeled SCPx across the peroxisomal membrane occurs upstream of the first
cytosolic ATP-dependent step, i.e., before PEX5 monoubiquitination. According to
current models, there are only two events occurring at the peroxisome before this first
ATP-dependent step: 1) docking of the PEX5-cargo protein complex at the DTM and
2) insertion of PEX5 into this machinery. It should be noted, however, that while there
is several experimental evidence supporting the concept that PEX5 becomes inserted
into the DTM in a cargo-dependent but ATP-independent manner (Gouveia et al,
2003b, 2000; Miyata & Fujiki, 2005; Oliveira et al, 2003), data regarding the docking
step itself are still very scarce. Actually, it is presently unknown whether such a step
really exists mechanistically, or if docking and insertion of PEX5 into the DTM are
simply the beginning and the end of a single step. To discriminate between these two
possibilities, we explored the fact that insertion of PEX5 into the DTM is inhibited at
low temperatures (Costa-Rodrigues et al, 2004) and asked whether docking of the
PEX5-cargo protein complex can still occur under those conditions. For this purpose,
radiolabeled SCPx was pre-incubated with a mixture of recombinant and radiolabeled
PEX5(C11A) and subjected to import assays at different temperatures allowing us to
monitor the behavior of both the cargo protein and the receptor simultaneously. After
the import reaction, samples were halved, treated or not with PK, and analyzed by
SDS-PAGE/Western-blotting/autoradiography.
As shown in Figure 17, PEX5(C11A) cannot be inserted into the DTM at low
temperatures (as assessed by the acquisition of a protease-resistant status; (Gouveia
et al, 2003a; Costa-Rodrigues et al, 2004)); insertion of PEX5(C11A) into the DTM
can only be detected at temperatures above 8 ºC (Figure 17, compare lanes 2-3 with
lanes 4-6). Importantly, the same temperature dependence profile is observed for the
import of SCPx, suggesting that it only occurs when PEX5 gets inserted into the DTM.
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Interestingly, when the protease treatment was omitted, considerable
amounts of both 35S-labeled PEX5(C11A) and SCPx were found in the organelle
fractions, even in import reactions performed at low temperatures (Figure 17, lanes 7-
8). To assess if these proteins are specifically adsorbed to peroxisomes, radiolabeled
SCPx and PEX5(C11A) pre-incubated as described above, were subjected to import
assays at 0 ºC or 37 ºC in the presence of either recombinant ΔC1PEX5 or the
negative control PEX19. As shown in Figure 18, a considerable fraction of both
radiolabeled PEX5(C11A) and SCPx was indeed specifically adsorbed to the
peroxisome because assays containing recombinant ΔC1PEX5, a PEX5 protein that
lacks the PTS1-binding domain but that is still competent in entering the DTM
(Gouveia et al, 2003b; Grou et al, 2012), have smaller amounts of the radiolabeled
proteins than those observed in the presence of PEX19 (Figure 18, compare lanes 2
and 4 with lanes 6 and 8, respectively).
Figure 17. Temperature dependence of the docking/insertion of PEX5 into the DTM and SCPx
import.
35S-SCPx pre-incubated with a mixture of recombinant and 35S-labeled PEX5(C11A) was subjected to
import assays at different temperatures. After 15 min, the samples were halved and treated (lanes +)
or not (lanes –) with proteinase K (PK). The organelles were analyzed by SDS-PAGE/autoradiography
(upper panel). The Ponceau S-stained membrane is also shown (lower panel). Lane 1 contains 5% of
the radiolabeled proteins used in the assays. Numbers to the left indicate the molecular masses of
protein standards in kDa.
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A similar competition phenomenon was observed when organelles isolated
from an import assay performed at 0 ºC were washed in buffer containing ΔC1PEX5
but not when it contained PEX19 (Figure 19, compare lanes 3 and 4 with lanes 5 and
6, respectively). Thus, both 35S-labeled PEX5(C11A) and SCPx can interact
specifically and reversibly with peroxisomes.
Taken together, these data reveal the existence of a mechanistically distinct
docking step of the PEX5-cargo protein complex at the DTM and suggest that import
of SCPx occurs concomitantly with insertion of PEX5 into the DTM.
Figure 18. Specific docking of 35S-PEX5(C11A) and 35S-SCPx at the peroxisome.
35S-SCPx pre-incubated with a mixture of recombinant and 35S-labeled PEX5(C11A) was subjected to
import assays at 0 ºC or 37 ºC in the presence of either recombinant ΔC1PEX5 or PEX19 (5 μM each),
as indicated. Protease-treated and untreated organelles were then analyzed as in Figure 17. Lane 1
contains 5% of the radiolabeled proteins used in the assays. Numbers to the left indicate the molecular
masses of protein standards in kDa.
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Figure 19. The docking step is reversible.
Organelles from an import assay containing 35S-SCPx and 35S-PEX5(C11A) performed at 0 ºC (lane 2)
were resuspended in import buffer containing either recombinant ΔC1PEX5 or PEX19, incubated for
15 min and re-isolated by centrifugation. Organelle pellets (P) (lanes 3 and 5) and the corresponding
supernatants (S) (lanes 4 and 6) were analyzed as in Figure 17. Lane 1 contains 5% of the
radiolabeled proteins used in the assays. Numbers to the left indicate the molecular masses of protein
standards in kDa.
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In mammals and many other organisms, import of all cargo proteins into the
peroxisomal matrix relies on the peroxisomal shuttling receptor, PEX5 (Otera et al,
1998; Braverman et al, 1998; Galland et al, 2007; Woodward & Bartel, 2005). The
pathway followed by PEX5 during this process has been extensively studied over the
years and is now known with reasonable detail (Grou et al, 2009a; Hu et al, 2012; Liu
et al, 2012; Platta et al, 2012). However, crucial aspects of the import process such
as the timing of the cargo translocation step are still poorly defined. To address these
issues, a cargo-centered perspective was required. As referred in section 4.1., low
import yields are usually obtained when using PTS1 proteins as reporters in in vitro
import assays. Therefore, our laboratory has recently developed an in vitro import
system centered in a PTS2 cargo protein, pre-thiolase (Alencastre et al, 2009). The
data obtained strongly suggest that the translocation of pre-thiolase across the
peroxisomal membrane as well as its processing and release into the peroxisomal
matrix, occurs before PEX5 monoubiquitination and does not require cytosolic ATP
hydrolysis (Alencastre et al, 2009). However, PTS2 proteins have the particularity to
require PEX7 for their peroxisomal targeting, a protein that has been suggested to
enter the organelle matrix together with the PTS2 proteins (Nair et al, 2004; Lazarow,
2006; Kunze et al, 2011; Braverman et al, 1997, 1998; Otera et al, 1998). Therefore,
it remained unclear whether the mechanistic data gathered for PTS2 proteins is a
general property of the peroxisomal protein import machinery or a unique feature of
the PTS2 import pathway. The main aim of this work was thus to dissect the import
mechanism of a PTS1 protein and thus to define the general properties of protein
translocation across the mammalian peroxisomal membrane.
To fulfill this task, it was necessary to develop an efficient and robust PTS1-
centered in vitro import system. To overcome the competition problems imposed by
endogenous soluble PTS1 proteins, a new strategy was developed: the reporter
PTS1 protein was pre-incubated with recombinant PEX5 prior to the in vitro import
reaction. This pre-incubation step allows the reporter protein to interact with PEX5
with no competition from endogenous PTS1 proteins of the PNS, and resulted in a
remarkable improvement of the in vitro import yields of several PTS1 proteins,
including SCPx (this work and unpublished results).
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After establishing the robustness and specificity of this PTS1-centered in vitro
import system, the import mechanism of SCPx was characterized. The results
obtained strongly suggest that the import of radiolabeled SCPx into peroxisomes
does not require monoubiquitination of PEX5 or the hydrolysis of cytosolic ATP. To
exclude the possibility that the ability to be imported into peroxisomes in a PEX5
monoubiquitination- and cytosolic ATP-independent manner is a particularity of SCPx,
identical experiments were performed with another PTS1 protein, DECR2. Similarly,
neither the use of the non-hydrolyzable ATP analog, AMP-PNP, nor the depletion of
ATP from import reactions affected the PEX5-mediated import of DECR2.
The fact that a protein acquires a protease-protected status when subjected
to an import assay suggests that no major portion of its polypeptide chain is exposed
into the cytosol, but does not discriminate between a protein that has already
translocated into the peroxisomal matrix from a species that is still associated with the
DTM. To clarify this issue, protease-treated organelles were disrupted by sonication,
and separated into soluble and membrane fractions. Remarkably and independently
of the energetic conditions used, the behavior of radiolabeled SCPx in these
experiments was exactly the one observed for endogenous SCPx, thus suggesting
that the radiolabeled protein had already translocated into the matrix of the organelle.
Consequently, neither ubiquitination of PEX5 at the DTM, nor the ATP-dependent
extraction of monoubiquitinated PEX5 from the DTM, seem to play a role in the
release of the cargo protein from the DTM into the peroxisomal matrix.
The conclusion that import of a PTS1 protein occurs upstream of PEX5
monoubiquitination immediately indicates that translocation of the cargo protein
across the organelle membrane occurs during the docking/insertion of PEX5 at/into
the DTM. By performing import reactions at several temperatures, it was possible to
determine for the first time that the docking at the peroxisomal membrane and
insertion of PEX5 into the DTM are two independent steps. Importantly, the
temperature-dependence profiles of both radiolabeled PEX5 insertion into the DTM
and radiolabeled SCPx import were the same, strongly supporting the idea that the
two events are coupled.
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Presently, there are two major models aiming at explaining how peroxisomal
matrix proteins reach the organelle matrix. The first model was proposed by our
laboratory several years ago and postulates that the driving force for protein
translocation across the organelle membrane resides in the strong protein-protein
interactions established between PEX5 and the DTM (Oliveira et al, 2003; Azevedo et
al, 2004). According to this model, chemical energy input (i.e., ATP hydrolysis) is only
necessary to extract PEX5 from the DTM, that is, to reset the peroxisomal import
machinery. The data supporting this model are abundant and have been summarized
previously (see section 1.3.3.2.).
The second model was recently published by the Erdmann group under the
name “export-driven protein import model” (Schliebs et al, 2010). For the sake of
completeness, we must note that this “model”, as proposed by the authors, actually
comprises two different models. The first version proposes that ubiquitination/export
of the shuttling receptors is necessary to generate free DTM so that protein import
can continue. In other words, ATP is needed to reset the PIM. Obviously, this version
of the “export-driven protein import model” is nothing else other than the model our
laboratory proposed several years before (Oliveira et al, 2003; Azevedo et al, 2004)
and has been refining since then (Grou et al, 2009a; Francisco et al, 2013). Therefore
we will make no further comments on this issue. The second version of the “export-
driven protein import model” hypothesizes that monoubiquitination/export of the
shuttling receptors is mechanistically linked to cargo translocation across the
peroxisome membrane. In other words, in the absence of monoubiquitination/export
of the receptors no cargo translocation can occur. The data obtained in this work,
together with findings previously obtained in our laboratory for PTS2 proteins
(Alencastre et al, 2009), clearly demonstrate that this is not the case, at least for the
mammalian PIM.
In summary, the results presented here suggest that translocation of a PTS1
protein across the organelle membrane, including its release into the peroxisomal
matrix, occurs downstream of the docking step and upstream of PEX5 ubiquitination,
concomitantly with the insertion of the receptor into the DTM. These findings provide
a hitherto missing cargo-centered perspective to support the model proposed by our
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group, in which PEX5, besides working as a soluble receptor, also functions as a
translocator pushing cargo proteins across the peroxisomal membrane as it gets
inserted into the peroxisomal docking/translocation machinery (see Figure 20).
Figure 20. Working model for the PEX5-mediated protein import pathway. After binding a PTS1
protein in the cytosol, PEX5 docks at the DTM in a reversible manner. PEX5 then becomes inserted
into the DTM pushing the cargo protein across the organelle membrane. In contrast to PEX5 recycling,
which includes monoubiquitination and PEX1/PEX6-catalyzed extraction of the receptor from the DTM,
the docking and translocation steps do not require cytosolic ATP.
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                     
                  
          
                 
                  
              
          
      
          
       
  
   

          
        
    
      
        
          
          
   
        
          
     
         
          
      
         
     
             
               
         
           
          
       
           
            
            
              
          
            
       
         
              
        
           
      
            
         
        
         
           
        
             
         
          
        
           
           
          
         
          
             
        
           
       
         
         
       
           
            
         
         
               
        
      
          
 
           
           
             
          
            
             
             
          
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